{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "error\n",
      "error\n"
     ]
    }
   ],
   "source": [
    "import os\n",
    "\n",
    "from langchain.chains import RetrievalQA\n",
    "from PyPDF2 import PdfReader\n",
    "from langchain.callbacks.base import BaseCallbackHandler\n",
    "from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
    "from langchain_community.vectorstores import Neo4jVector\n",
    "from langchain_community.chat_models import ChatOllama\n",
    "from langchain_core.documents import Document\n",
    "import os\n",
    "import json\n",
    "from semantic_text_splitter import TextSplitter\n",
    "# load api key lib\n",
    "from dotenv import load_dotenv\n",
    "from langchain_community.embeddings import HuggingFaceBgeEmbeddings\n",
    "from langchain.chains import RetrievalQA\n",
    "from langchain_community.embeddings import OllamaEmbeddings\n",
    "from langchain_community.embeddings import HuggingFaceEmbeddings\n",
    "from langchain_community.embeddings import HuggingFaceInferenceAPIEmbeddings\n",
    "from langchain_community.embeddings import HuggingFaceHubEmbeddings\n",
    "from langchain.chains import RetrievalQA,RetrievalQAWithSourcesChain\n",
    "from langchain.memory import ConversationSummaryBufferMemory\n",
    "from langchain.vectorstores import Chroma\n",
    "from langchain.retrievers import ParentDocumentRetriever\n",
    "from langchain_text_splitters import RecursiveCharacterTextSplitter\n",
    "from langchain_core.documents import Document\n",
    "from langchain.storage import InMemoryStore\n",
    "from langchain.vectorstores import FAISS\n",
    "import os\n",
    "\n",
    "\n",
    "embeddings_options=[\"medllama2\",\"huggingface\"]\n",
    "\n",
    "embeddings_name=embeddings_options[0]\n",
    "\n",
    "load_dotenv(\".env\")\n",
    "\n",
    "url = \"neo4j://localhost:7687\"\n",
    "# url = \"neo4j://localhost:7474\"\n",
    "username =\"neo4j\"\n",
    "password = \"password\"\n",
    "\n",
    "os.environ[\"NEO4J_URI\"] = url #\"bolt://localhost:7687\"\n",
    "os.environ[\"NEO4J_USERNAME\"] =username # \"neo4j\"\n",
    "os.environ[\"NEO4J_PASSWORD\"] = password #\"password\"\n",
    "\n",
    "\n",
    "url = os.getenv(\"NEO4J_URI\")\n",
    "username = os.getenv(\"NEO4J_USERNAME\")\n",
    "password = os.getenv(\"NEO4J_PASSWORD\")\n",
    "ollama_base_url = os.getenv(\"OLLAMA_BASE_URL\")\n",
    "embedding_model_name = os.getenv(\"EMBEDDING_MODEL\")\n",
    "llm_name = \"medllama2\"#os.getenv(\"LLM\")\n",
    "# Remapping for Langchain Neo4j integration\n",
    "os.environ[\"NEO4J_URL\"] = url\n",
    "\n",
    "\n",
    "\n",
    "if(embeddings_name==embeddings_options[0]):\n",
    "    embeddings = OllamaEmbeddings(\n",
    "                model=\"medllama2\"\n",
    "            )\n",
    "if(embeddings_name==embeddings_options[1]):\n",
    "    # model = \"sentence-transformers/all-mpnet-base-v2\"\n",
    "    model = \"ncbi/MedCPT-Query-Encoder\"\n",
    "    embeddings = HuggingFaceHubEmbeddings(\n",
    "    model=model,\n",
    "    task=\"embedding\",\n",
    "    huggingfacehub_api_token=\"xxx\",\n",
    ")\n",
    "\n",
    "max_characters = 200\n",
    "# Optionally can also have the splitter not trim whitespace for you\n",
    "splitter = TextSplitter()\n",
    "\n",
    "# Document(page_content=sect['text'])\n",
    "\n",
    "# folder_path = \"/workspaces/thyroid_knowledge_graph/preprocessed\"\n",
    "folder_path = \"/workspaces/thyroid_knowledge_graph/preprocessed_full_new_biblio\"\n",
    "file_paths = []\n",
    "\n",
    "for root, dirs, files in os.walk(folder_path):\n",
    "    for file in files:\n",
    "        file_path = os.path.join(root, file)\n",
    "        file_paths.append(file_path)\n",
    "\n",
    "texts=[]\n",
    "texts_dict={}\n",
    "for file_path in file_paths:\n",
    "    index=0\n",
    "    with open(file_path, 'r') as file:\n",
    "        data = json.load(file)\n",
    "        try:\n",
    "            sections= data['sections']\n",
    "            data_loc=[]\n",
    "\n",
    "            for sect in sections:\n",
    "                \n",
    "                # keyy=f\"{os.path.basename(file_path)}___{index}\"\n",
    "                # texts.append(Document(page_content=sect['text'],metadata={\"source\":keyy ,\"num\":index}))   \n",
    "                # texts_dict[keyy]=sect['text']\n",
    "                # res.append(sect['text'])\n",
    "                for chunk in splitter.chunks(sect['text'], max_characters):\n",
    "                    index=index+1\n",
    "                    keyy=f\"{os.path.basename(file_path)}___{index}\"\n",
    "                    texts.append(Document(page_content=chunk,metadata={\"source\": keyy,\"num\":index})) \n",
    "                    texts_dict[keyy]=sect['text']\n",
    "\n",
    "        except:\n",
    "            print(\"error\")\n",
    "                \n",
    "            # data_loc.append(sect['text'],)\n",
    "        # data_loc=\"\\n\".join(data_loc)\n",
    "        # res.append(Document(page_content=data_loc,metadata={\"source\": file_path}))     \n",
    "        \n",
    "\n",
    "\n",
    "llm_med = ChatOllama(model=\"medllama2\")\n",
    "\n",
    "# texts=texts[0:100] #TODO remove\n",
    "\n",
    "\n",
    "#memory for retriever\n",
    "# memory = ConversationSummaryBufferMemory(llm=llm_med, input_key='question', output_key='answer', return_messages=True)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(page_content='The putative first description of C cells can be attributed to E.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___1', 'num': 1}),\n",
       " Document(page_content='Cresswell Baber in the thyroid gland of the dog in 1876; he suspected that sheets of cells situated between the \"vesicles\" (i.e. follicles) represent the regeneration pool of the \"vesicles\" (Baber', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___2', 'num': 2}),\n",
       " Document(page_content='1876). In 1894, Karl Hürthle described in his only publication dealing with the thyroid cell complexes in dog thyroid which he called \"interfollicular epithelium\" (Hürthle 1894).', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___3', 'num': 3}),\n",
       " Document(page_content='Later, these cells were confused with follicular-derived elements such as oncocytic cells, leading particularly in the Anglo-American usage to the still common but erroneous designation \"Hürthle cells', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___4', 'num': 4}),\n",
       " Document(page_content='\" as a synonym for oncocytes.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___5', 'num': 5}),\n",
       " Document(page_content='In 1932, José F.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___6', 'num': 6}),\n",
       " Document(page_content='Nonidez identified in the thyroid of the dog the exclusively between the follicles of the thyroid situated C cells as a second component of the thyroid epithelium and coined them \"parafollicular cells', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___7', 'num': 7}),\n",
       " Document(page_content='\" (Nonidez 1932). However, in humans, normal C cells are predominantly located within the thyroid follicles (Fig. 1), with less than 1 % of C cells in a parafollicular location.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___8', 'num': 8}),\n",
       " Document(page_content='Thus, the term \"parafollicular cells\" as a synonym for human C cells should be avoided.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___9', 'num': 9}),\n",
       " Document(page_content='Some decades later, electron microscopic studies supported the observation (DeLellis et al. 1978) that human C cells are indeed intrafollicular and separated from the thyroid interstitium by the', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___10', 'num': 10}),\n",
       " Document(page_content='follicular basement membrane.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___11', 'num': 11}),\n",
       " Document(page_content='C cells contain moderately electron-dense larger (type I; 280 nm) and more electron-dense smaller (type II; 130 nm) secretory granules; ultrastructural immunohistochemistry demonstrated the peptide', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___12', 'num': 12}),\n",
       " Document(page_content='hormone calcitonin in both type I and type II granules. Besides, these granules C cells contain abundant endoplasmic reticulum and mitochondria.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___13', 'num': 13}),\n",
       " Document(page_content='All these structures are also detectable in hyperplastic and neoplastic C cells.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___14', 'num': 14}),\n",
       " Document(page_content='The majority of C cells in the human thyroid gland are originating from primordial C cells of the neural crest, which migrate ventrally to the ultimobranchial body (a derivative of the ventral recess', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___15', 'num': 15}),\n",
       " Document(page_content='of the fourth pharyngeal pouch). These C cells are thus of neuroectodermal origin.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___16', 'num': 16}),\n",
       " Document(page_content='During the descent of the thyroid, the ultimobranchial body is incorporated into both thyroid lobes, ideally leading to a disperse distribution of the C cells in preferred regions of the thyroid lobes', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___17', 'num': 17}),\n",
       " Document(page_content='(see below). Apparently in most humans, the ultimobranchial body is completely incorporated into the thyroid lobes.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___18', 'num': 18}),\n",
       " Document(page_content='However, occasionally C cells remain along their migration path in extrathyroidal location and may give rise to pathological processes of C cells (hyperplasia and neoplasia) outside the thyroid (', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___19', 'num': 19}),\n",
       " Document(page_content='Hirsch et al. 2004;Smets et al. 1990). Disturbances in the intrathyroidal distribution result in focal accumulation of C cells (Gibson et al. 1980).', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___20', 'num': 20}),\n",
       " Document(page_content='Studies in thyroid glands of patients with DiGeorge syndrome confirmed on the one hand the origin of C cells from the ultimobranchial body (Pueblitz et al. 1993), and on the other hand, they suggest', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___21', 'num': 21}),\n",
       " Document(page_content='that a (small) subset of C cells most likely arise from endodermal stem cells (Harach 1997).', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___22', 'num': 22}),\n",
       " Document(page_content='In the thyroid, three types of epithelial cells can be distinguished: follicular cells accounting for more than 99.9 % of all thyroid epithelia, C cells (0.01-0.1 %) and the only occasionally', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___23', 'num': 23}),\n",
       " Document(page_content='demonstrable so-called solid cell nests (SCN); the latter most likely represent remnants of the ultimobranchial body, which is supported by the calcitonin production of SCN.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___24', 'num': 24}),\n",
       " Document(page_content=\"The number of C cells is higher in newborns than in adults and increases again after 60 years of age (O'Toole et al. 1985).\", metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___25', 'num': 25}),\n",
       " Document(page_content='C cells are mainly confined to groups of thyroid lobules located centrally in the rear upper portions of both thyroid lobes.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___26', 'num': 26}),\n",
       " Document(page_content='At the poles of the thyroid lobes, the isthmus and pyramidal lobe C cells are detectable in significantly reduced numbers or completely missing.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___27', 'num': 27}),\n",
       " Document(page_content='Thus, medullary thyroid carcinoma (MTC) may occur in all parts of the thyroid; however, it can be found more frequently in areas of high C-cell concentration than in the peripheral thyroid.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___28', 'num': 28}),\n",
       " Document(page_content='Histologically, C cells are difficult to identify on routine H&E sections; usually, calcitonin immunohistochemistry is performed to demonstrate C cells on the light microscopical level (LiVolsi 1990).', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___29', 'num': 29}),\n",
       " Document(page_content='The majority of C cells (size up to 40 µm) are round or polygonal, found singly or in groups of 3-5 cells. A second type of C cells is spindled shaped with tapered ends (Ljungberg 1972;Schmid et al.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___30', 'num': 30}),\n",
       " Document(page_content='1992). Virtually, all C cells are situated within the follicular basement membrane.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___31', 'num': 31}),\n",
       " Document(page_content='The term \"C cell\" was introduced by Copp and Cameron in 1961, who postulated in isolated thyroid and parathyroid glands of dogs a type of cell producing and secreting a hormone \"calcitonin\" with', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___32', 'num': 32}),\n",
       " Document(page_content='calcium-lowering effect (Copp and Cameron 1961); however, initially, the parathyroid glands were assumed as the origin of the hormone (Copp et al. 1962).', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___33', 'num': 33}),\n",
       " Document(page_content='In 1964, it was recognized that calcitonin originates from the thyroid gland (Foster et al. 1964); in 1967 (Tauber 1967), the previously postulated \"C cells\" were morphologically demonstrated in the', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___34', 'num': 34}),\n",
       " Document(page_content='thyroid gland and their neuroectodermal origin was revealed. Already in 1966, E. Dillwyn Williams had predicted the until then postulated C cells as the source of MTC (Williams 1966).', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___35', 'num': 35}),\n",
       " Document(page_content='In 1973, Hubert J. Wolfe recognized that C-cell hyperplasia (CCH) is an obligatory precursor of hereditary MTC (Wolfe et al. 1973).', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___36', 'num': 36}),\n",
       " Document(page_content='Almost all human C cells synthesize and secrete calcitonin; only in a small fraction of the C cells exclusively calcitonin gene-related peptide (CGRP) is detectable.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___37', 'num': 37}),\n",
       " Document(page_content='Calcitonin is a 32-amino acid linear polypeptide hormone.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___38', 'num': 38}),\n",
       " Document(page_content='Structurally, calcitonin has an intramolecular disulphide bridge (Cys-1 to Cys-7) and an amidated C-terminus; both are essential for the biological activity of the hormone.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___39', 'num': 39}),\n",
       " Document(page_content='Disulphide bridge-free calcitonin is able to bind specifically to the calcitonin receptor; however, it acts at the receptor as a competitive antagonist.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___40', 'num': 40}),\n",
       " Document(page_content='The neuropeptide CGRP consists of 37 amino acids and is encoded by the same gene as calcitonin; it occurs predominantly in the peripheral and central nervous system and to a lesser extent in the', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___41', 'num': 41}),\n",
       " Document(page_content='thyroid by selective mRNA splicing.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___42', 'num': 42}),\n",
       " Document(page_content='An increase of serum calcium in the blood, gastrointestinal hormones and pentagastrin (a synthetic oligopeptide with gastrin effect) stimulate calcitonin secretion.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___43', 'num': 43}),\n",
       " Document(page_content='To lower the serum calcium level, calcitonin induces a decreased osteoclastic activity in the bone, an increased calcium excretion from the kidney and a reduced resorption of calcium in the intestine.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___44', 'num': 44}),\n",
       " Document(page_content='However, the efficacy of calcitonin in the regulation of calcium in comparison with the other calcium-regulating hormones calcitriol and parathyroid hormone is relatively limited.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___45', 'num': 45}),\n",
       " Document(page_content='An increase in size and number of C cells is called CCH.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___46', 'num': 46}),\n",
       " Document(page_content='The term CCH refers, however, to two different C-cell conditions with completely different pathological potential (Albores-Saavedra and Krueger 2001;LiVolsi 1997;Perry et al. 1996).', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___47', 'num': 47}),\n",
       " Document(page_content='Inherited \"neoplastic C-cell hyperplasia\", by definition always associated with germline mutation of the RET proto-oncogene, is the precursor lesion of familial MTC and can easily be identified on H&E', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___48', 'num': 48}),\n",
       " Document(page_content='sections (DeLellis et al. 2004). The enlarged, pale C cells are mainly located in areas of high C-cell concentration (Ting et al. 2015).', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___49', 'num': 49}),\n",
       " Document(page_content='Neoplastic CCH is found in prophylactic thyroidectomy specimens of asymptomatic carriers of the RET-mutation or patients with MTC usually in close vicinity of (multifocal) invasive familial MTC.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___50', 'num': 50}),\n",
       " Document(page_content='Morphologically, neoplastic CCH is characterized by groups of atypical cells situated within the thyroid follicular basement membrane (focal CCH); these cells may encircle the entire follicular lumen', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___51', 'num': 51}),\n",
       " Document(page_content='(diffuse CCH; Fig. 2) and ultimately obliterate the follicular lumen partially or completely (nodular CCH; Fig. 3).', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___52', 'num': 52}),\n",
       " Document(page_content='Neoplastic CCH may be difficult to distinguish from SCN, palpation thyroiditis and occasionally papillary microcarcinoma (Elisei et al. 2008;Schmid and Sheu 2015).', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___53', 'num': 53}),\n",
       " Document(page_content='In contrast, \"non-MEN2-associated CCH\" (Ting et al. 2015), previously named \"sporadic\" or \"physiological\" CCH (Perry et al. 1996), cannot be identified on H&E sections (DeLellis et al. 2004); its', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___54', 'num': 54}),\n",
       " Document(page_content='identification requires immunohistochemical calcitonin demonstration (Fig. 4).', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___55', 'num': 55}),\n",
       " Document(page_content='Non-MEN2-associated CCH is defined as an increase of normally appearing C cells; at 100-fold magnification, at least 50 C cells (calcitonin immunohistochemistry) have to be identified in areas of high', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___56', 'num': 56}),\n",
       " Document(page_content='C-cell concentration (Rosai et al. 1992). Occasionally, non-MEN2-associated CCH can also show focal obliteration of follicles.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___57', 'num': 57}),\n",
       " Document(page_content='Non-MEN2-associated CCH has been described in association with a great variety of pathological conditions, including non-medullary thyroid tumours (Albores-Saavedra et al.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___58', 'num': 58}),\n",
       " Document(page_content='1988;Scheuba et al. 2000), autoimmune thyroiditis Hashimoto and thyroid non-Hodgkin-lymphoma (Baschieri  (Scheuba et al. 2000), in the vicinity of SCN (Chan and Tse 1989), renal failure and calcium', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___59', 'num': 59}),\n",
       " Document(page_content='metabolism disorders. Up to 50 % of patients with nodular goitre (age-and sex-independent) show a morphologically detectable non-MEN2-associated CCH without increased serum calcitonin (Kaserer et al.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___60', 'num': 60}),\n",
       " Document(page_content='1998).', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___61', 'num': 61}),\n",
       " Document(page_content='To the best of knowledge, this form of CCH is not related to the development of sporadic MTC; so far, no somatic mutations of the RET proto-oncogene could be demonstrated in the C cells of \"non-MEN2-', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___62', 'num': 62}),\n",
       " Document(page_content='associated\" CCH (Saggiorato et al. 2007).', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___63', 'num': 63}),\n",
       " Document(page_content='The differential diagnosis of neoplastic CCH from microinvasive familial MTC may cause severe difficulties (DeLellis et al. 2004).', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___64', 'num': 64}),\n",
       " Document(page_content='Microinvasive MTC is characterized by defects of the follicular basement membrane (Rosai et al. 1992) which are virtually impossible to demonstrate on routine H&E sections.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___65', 'num': 65}),\n",
       " Document(page_content='However, this is regularly accompanied by the development of stromal desmoplasia around the tumour cell nests which is a useful and reliable surrogate marker of tumour cell invasion (Sheu and Schmid', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___66', 'num': 66}),\n",
       " Document(page_content='2010;Fig. 5).', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___67', 'num': 67}),\n",
       " Document(page_content='In some cases, the neoplastic C-cell aggregates are measuring several millimetres apparently without developing stromal desmoplasia (Fig. 6a,b); due to their size, these lesions are classified as MTC', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___68', 'num': 68}),\n",
       " Document(page_content='although no generally accepted consensus on this issue exists.  In 1951, Robert C.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___69', 'num': 69}),\n",
       " Document(page_content='Horn described (Horn 1951) a series of seven cases of a variant of thyroid carcinoma with solid growth pattern and amyloid, which he classified subsequently as poorly differentiated and highly', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___70', 'num': 70}),\n",
       " Document(page_content='malignant (Horn and Dull 1951).', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___71', 'num': 71}),\n",
       " Document(page_content='The term \"MTC\" was coined in 1959 by Hazard et al. based on a series of 21 thyroid carcinomas, again morphologically appearing as solid tumours with amyloid deposits; biologically, the tumours were', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___72', 'num': 72}),\n",
       " Document(page_content='considered to have an intermediate position between differentiated (papillary and follicular thyroid carcinoma) and anaplastic thyroid carcinomas (Hazard et al. 1959). In 1966, E.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___73', 'num': 73}),\n",
       " Document(page_content='Dillwyn Williams recognized striking similarities between human medullary carcinoma and thyroid tumours in dog and rat originating from \"parafollicular cells\" (Williams 1966).', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___74', 'num': 74}),\n",
       " Document(page_content='He proposed that human medullary carcinoma might be derived from the to that time in men still postulated C cells, and he predicted that if the C cells were the source of calcitonin, medullary', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___75', 'num': 75}),\n",
       " Document(page_content='carcinoma might also produce this hormone.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___76', 'num': 76}),\n",
       " Document(page_content='In 1968, Meyer and Abdel-Bari demonstrated electronmicroscopically secretory granules in the tumour cells as well as biochemically a 100-fold increased calcitonin concentration in the tumour compared', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___77', 'num': 77}),\n",
       " Document(page_content='to normal thyroid tissue (Meyer and Abdel-Bari 1968). Using immunofluorescence, Bussolati et al. demonstrated in 1969 calcitonin in the cells of medullary (Bussolati et al. 1969).', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___78', 'num': 78}),\n",
       " Document(page_content='In 1886, Felix Fränkel reported of an already 1884 performed autopsy of a 18-year-old female patient with bilateral adrenal tumours (then interpreted as an angiosarcoma) and goitre (Fränkel 1886);', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___79', 'num': 79}),\n",
       " Document(page_content='this is considered to be the first description of a case of multiple endocrine neoplasias type 2A.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___80', 'num': 80}),\n",
       " Document(page_content='Over 120 years later, a germline mutation in the RET proto-oncogene at codon 634 TCG > TGG (C634W) was demonstrated on the still available tissue specimens of the patient; subsequently, descendants of', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___81', 'num': 81}),\n",
       " Document(page_content='brothers of the patient suffering from pheochromocytomas and MTC were identified (Neumann et al. 2007). John H.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___82', 'num': 82}),\n",
       " Document(page_content='Sipple described in 1961 the combination of pheochromocytoma with adenocarcinoma of the thyroid (Sipple 1961); subsequently, the combination was recognized as the (autosomal-dominant inherited)', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___83', 'num': 83}),\n",
       " Document(page_content=\"syndrome of multiple neuroendocrine neoplasia (MEN) 2A (Steiner et al. 1968), in which the in all cases occurring MTC determines largely the patients' survival (Machens and Dralle 2006).\", metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___84', 'num': 84}),\n",
       " Document(page_content='The first description of a case with MEN 2B was made in 1922 by Wagenmann (1922) and Froebius (1922).', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___85', 'num': 85}),\n",
       " Document(page_content='Up to date, no benign C-cell tumour has been defined.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___86', 'num': 86}),\n",
       " Document(page_content='In familial MTC, malignancy is presumed when hyperplastic C cells show invasive growth through the follicular membrane which is accompanied by the development of a fibrous desmoplastic stroma (Rosai', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___87', 'num': 87}),\n",
       " Document(page_content='et al. 1992;Sheu and Schmid 2010;Fig. 5). This stromal desmoplasia is also observed in approximately 80 % of sporadic MTC.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___88', 'num': 88}),\n",
       " Document(page_content='However, in the remaining 20 % of sporadic MTC as well as in a number of familial MTC, stromal desmoplasia is completely lacking (Koperek et al. 2008); in these cases, which are usually well', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___89', 'num': 89}),\n",
       " Document(page_content='circumscribed but not necessarily enveloped by a tumour capsule, the diagnosis of MTC (by definition a malignant tumour!', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___90', 'num': 90}),\n",
       " Document(page_content='(DeLellis et al. 2004)) is apparently rather based on the size of the C-cell tumour than the demonstration of unequivocal invasive growth (Synoracki et al. 2015; Fig. 6a,b).', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___91', 'num': 91}),\n",
       " Document(page_content='MTC is mainly located in the lateral upper two-thirds of the thyroid lobes, the area of highest C-cell concentration; the tumours range in size from barely visible to several centimetres in diameter (', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___92', 'num': 92}),\n",
       " Document(page_content='LiVolsi 1990). In >90 %, familial MTC is associated with (small) multifocal and bilateral tumours, whereas in sporadic MTC, multifocality is the exception (Rosai et al. 1992;Schmid et al. 2003).', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___93', 'num': 93}),\n",
       " Document(page_content='In the isthmic region or the thyroid periphery, MTC is located only occasionally.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___94', 'num': 94}),\n",
       " Document(page_content='Macroscopically, MTC presents with a greyish-white to reddish-brown cutting surface; the tumours are often circumscribed and in rare cases even completely encapsulated.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___95', 'num': 95}),\n",
       " Document(page_content='On the other hand, occasionally even very small tumours (<7 mm) may macroscopically already show infiltrative borders (Chan 2007).', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___96', 'num': 96}),\n",
       " Document(page_content='With increasing size, the tumours may regularly develop haemorrhage, cystic regressions and/or in large tumours central necrosis (DeLellis et al. 2004).', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___97', 'num': 97}),\n",
       " Document(page_content='The histopathological appearance of MTC is exceptionally variable (DeLellis et al. 2004;LiVolsi 1990;Rosai et al. 1992;Synoracki et al. 2015).', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___98', 'num': 98}),\n",
       " Document(page_content='MTC may mimic a broad variety of thyroid and non-thyroid tumours; thus, every unusual thyroid tumour should be investigated using calcitonin immunohistochemistry in order to prove or exclude MTC (', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___99', 'num': 99}),\n",
       " Document(page_content='Schmid et al. 2003).', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___100', 'num': 100}),\n",
       " Document(page_content='The typical MTC shows a solid and compact growth pattern of nests of polygonal-and spindle-shaped tumour cells which regularly freely infiltrate into the surrounding non-neoplastic thyroid tissue.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___101', 'num': 101}),\n",
       " Document(page_content='The cytoplasm of the tumour may appear granulated, and the predominantly uniform round-to-oval nuclei show a coarsely granulated chromatin (\"salt-and-pepper pattern\").', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___102', 'num': 102}),\n",
       " Document(page_content='The number of mitosis found is quite variable.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___103', 'num': 103}),\n",
       " Document(page_content='The tumour stroma may show delicate collagen bands without stromal desmoplasia; MTC without stromal desmoplasia is statistically significantly associated with a very low potential for metastasis (', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___104', 'num': 104}),\n",
       " Document(page_content='Koperek et al. 2008;Scheuba et al. 2006). So far, no specific immunohistochemical and/or molecular markers have been found further characterize MTC without stromal desmoplasia (Koperek et al.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___105', 'num': 105}),\n",
       " Document(page_content='2007(Koperek et al. , 2009(Koperek et al. , 2011)).', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___106', 'num': 106}),\n",
       " Document(page_content='In the majority of MTC (approx. 80 %), stromal desmoplasia, indicating invasive growth of tumour cells, can be demonstrated; however, the extent of stromal desmoplasia may vary considerable.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___107', 'num': 107}),\n",
       " Document(page_content='Amyloid deposits are present in 60-85 % of MTC cases.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___108', 'num': 108}),\n",
       " Document(page_content='The demonstration of amyloid may be strongly suggestive for the diagnosis of MTC; however, since amyloid can be found in a variety of non-C-cell differentiated thyroid lesions, the diagnosis of MTC', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___109', 'num': 109}),\n",
       " Document(page_content='cannot be based exclusively on the demonstration of amyloid.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___110', 'num': 110}),\n",
       " Document(page_content='The papillary or pseudopapillary variant of MTC is characterized by the presence of true papillae or artificial pseudopapillary structures; the tumour cell nuclei are lacking the nuclear features of', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___111', 'num': 111}),\n",
       " Document(page_content='papillary carcinoma (Fig. 7). MTC with glandular features (follicular or trabecular) may cause differential diagnostic problems with adenomas and follicular carcinomas (Fig. 8).', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___112', 'num': 112}),\n",
       " Document(page_content='The insular variant of MTC may resemble poorly differentiated thyroid carcinoma or classical carcinoid.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___113', 'num': 113}),\n",
       " Document(page_content='Giant cell and spindle cell (Fig. 9) variants of MTC may be confused with anaplastic thyroid carcinoma; although these variants of MTC may show a less favourable outcome, the prognosis is still much', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___114', 'num': 114}),\n",
       " Document(page_content='better than that of anaplastic carcinoma. Small-cell variant of MTC, which is more commonly associated with tumour necrosis than other variants of MTC, is also associated with a poorer prognosis.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___115', 'num': 115}),\n",
       " Document(page_content='The oncocytic variant of MTC may be misdiagnosed as oncocytic (Hürthle cell) variants of other thyroid tumour entities; since oncocytic thyroid tumours with follicular cell differentiation may show a', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___116', 'num': 116}),\n",
       " Document(page_content='false-positive calcitonin immunoreactivity (due to the antibody clone used), the diagnosis of the oncocytic variant of MTC should be confirmed by additional immunohistochmical markers [e.g.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___117', 'num': 117}),\n",
       " Document(page_content='chromogranins, synaptophysin, carcinoembryonic antigen (CEA)].', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___118', 'num': 118}),\n",
       " Document(page_content='The paraganglioma-like variant of MTC (Fig. 10) contains numerous S-100-positive sustentacular cells; in contrast to this MTC variant, the rare primary intrathyroidal paraganglioma is negative for', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___119', 'num': 119}),\n",
       " Document(page_content='cytokeratins. The angiosarcomatoid variant of MTC (Fig. 11) is characterized by a variable number of vascular spaces containing erythrocytes.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___120', 'num': 120}),\n",
       " Document(page_content='Rarer variants of MTC include the clear cell, squamous cell, melanin-producing and amphicrine variants.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___121', 'num': 121}),\n",
       " Document(page_content='However, it has to be emphasized that the morphological variants of MTC rather highlight the danger of a misdiagnosis then represent \"real\" entities with a defined biological behaviour.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___122', 'num': 122}),\n",
       " Document(page_content='Calcitonin is expressed, although in considerable different quantity, in the vast majority of MTC (DeLellis et al. 2004;Harach et al. 1992;Krisch et al. 1985;Lloyd et al.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___123', 'num': 123}),\n",
       " Document(page_content='1983;Schmid and Ensinger 1998); by combined use of calcitonin and chromogranin A antibodies virtually, all MTC can be immunohistochemically detected (Harach et al. 1992).', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___124', 'num': 124}),\n",
       " Document(page_content='MTC expresses general neuroendocrine markers such as chromogranins (Schmid et al. 1987), synaptophysin and others (Chan 2007).', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___125', 'num': 125}),\n",
       " Document(page_content='Additionally, a broad variety of peptides (somatostatin, ACTH, serotonin, gastrin, bombesin, calcitonin gene-related peptide (CGRP) and others) can be demonstrated (Chan 2007;Schmid and Böcker 1993).', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___126', 'num': 126}),\n",
       " Document(page_content='CEA is expressed in most cases; in less differentiated MTC, CEA is usually stronger expressed than calcitonin (Lloyd et al. 1983;Schmid et al. 2003;Schröder and Klöppel 1987).', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___127', 'num': 127}),\n",
       " Document(page_content='Nuclear TTF-1 and Islet-1 expression can be found in most MTC (Agaimy et al. 2013).', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___128', 'num': 128}),\n",
       " Document(page_content='S-100 positive sustentacular cells can be regularly found in MTC (more often in familial than in sporadic MTC (Matias-Guiu et al. 1998)).', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___129', 'num': 129}),\n",
       " Document(page_content='Numerous S-100 positive sustentacular cells are the immunohistochemical hallmark of the paraganglioma-like variant of (sporadic) MTC (Bockhorn et al. 2005).', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___130', 'num': 130}),\n",
       " Document(page_content='Rarely, MTC may (almost completely) lack calcitonin and CEA expression (Bockhorn et al.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___131', 'num': 131}),\n",
       " Document(page_content='2004;Krisch et al. 1985); these tumours are referred to as \"atypical MTC\" (Schmid and Ensinger 1998) tumours of the thyroid with neuroendocrine features (immunohistochemistry) may represent metastases', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___132', 'num': 132}),\n",
       " Document(page_content='from other neuroendocrine carcinoma (predominatly from lung or gastrointestinal tract), an intrathyreoidal located parathyroid tumour or rare primary paraganglioma of the thyroid.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___133', 'num': 133}),\n",
       " Document(page_content='Due to the possibility of an incomplete incorporation of the ultimobranchial body during thyroid, decent rarely C cells may remain in an extrathyroidal location (in the region of the larynx and', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___134', 'num': 134}),\n",
       " Document(page_content='pharynx); these C cells can give rise to carcinomas with the morphological, immunohistochemical, biological and genetic features of a MTC (Hirsch et al. 2004;Insabato et al. 1993;Smets et al.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___135', 'num': 135}),\n",
       " Document(page_content='1990;Sweeney et al. 1981).', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___136', 'num': 136}),\n",
       " Document(page_content='Non-specific clinical symptoms are thyroid enlargement, dysphagia, hoarseness and enlarged lymph nodes; the development of severe watery diarrhoea in approximately 40 % of MTC is however specific (Liu', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___137', 'num': 137}),\n",
       " Document(page_content='et al. 2011). The survival of patients with MTC significantly depends on tumour expansion at the time of diagnosis.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___138', 'num': 138}),\n",
       " Document(page_content='MTC confined to the thyroid shows a long-term survival of >95 % (Girelli et al. 1998), whereas MTC associated with metastasis in cervical and/or upper mediastinal lymph nodes at the time of diagnosis', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___139', 'num': 139}),\n",
       " Document(page_content='has significantly worse prognosis (Erovic et al. 2012); distant metastases occurring in the course of the disease are predominantly found in the lungs, liver, bone and adrenal glands.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___140', 'num': 140}),\n",
       " Document(page_content='In general, MTC is a very slow-growing tumour, and patients can still survive even with distant metastases for several decades; compared with the normal population, however, disease-related mortality', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___141', 'num': 141}),\n",
       " Document(page_content='is significantly increased even 10 years after the diagnosis of MTC (Bergholm et al. 1997).', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___142', 'num': 142}),\n",
       " Document(page_content='Currently, the only curative therapeutic approach of MTC is the complete surgical removal of the primary tumour (and its lymph node metastases).', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___143', 'num': 143}),\n",
       " Document(page_content='For early detection of MTC, systematic routine calcitonin screening in patients with thyroid nodules has been introduced (Karges 2010;Vierhapper et al. 1997).', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___144', 'num': 144}),\n",
       " Document(page_content='The clinical management of affected members from known MEN 2 families crucially depends on the location of the RET proto-oncogene mutation (ATA risk levels A-D (Cooper et al.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___145', 'num': 145}),\n",
       " Document(page_content='2009); Table 1); ideally, prophylactic thyroidectomy is performed prior to the development of invasive MTC from neoplastic CCH (Table 2; Cooper et al. 2009;Sheu and Schmid 2010;Ting et al.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___146', 'num': 146}),\n",
       " Document(page_content='2015;Wohllk et al. 2010).', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___147', 'num': 147}),\n",
       " Document(page_content='The insights gained into the constitutive activation of the RET kinase led to the introduction of targeted therapies for locally advances and/or metastatic MTC.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___148', 'num': 148}),\n",
       " Document(page_content='Currently, two tyrosine kinase inhibitors are approved in Germany: vandetanib acts an inhibitor of RET kinase, but also of VEGFR and EGFR signalling pathways (Elisei et al. 2013).', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___149', 'num': 149}),\n",
       " Document(page_content='Cabozantinib is an inhibitor of the VEGFR 2 as well as VEGF and MET tyrosine kinases; additional effects were observed on RET, KIT and FLT3-AXL kinases (Wells et al. 2012).', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___150', 'num': 150}),\n",
       " Document(page_content='Whether molecular profiling of MTC has  Synoracki et al.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___151', 'num': 151}),\n",
       " Document(page_content='(2015), Wohllk et al. (2010) the potential to offer prediction of treatment response is yet unclear; however, the primarily with a less favourable clinical course associated somatic mutations of the', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___152', 'num': 152}),\n",
       " Document(page_content='RET proto-oncogene in MTC (Elisei et al. 2008) may probably mediate a better response to targeted therapies.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___153', 'num': 153}),\n",
       " Document(page_content='Author Disclosure Statement The author has nothing to disclose, no competing financial interests exist.', metadata={'source': 'Histopathology of C Cells and Medullary Thyroid Carcinoma.json___154', 'num': 154}),\n",
       " Document(page_content='levels (negative predictive value 100%).', metadata={'source': 'Ipsilateral Versus Bilateral Central Neck Lymph Node Dissection in Papillary Thyroid Carcinoma.json___1', 'num': 1}),\n",
       " Document(page_content='Prediction of lymph node metastasis was better in carriers of codon 918 mutations (positive predictive value, PPV, 80%-100%) and those older than 20 years of age (PPV, 50%).', metadata={'source': 'Ipsilateral Versus Bilateral Central Neck Lymph Node Dissection in Papillary Thyroid Carcinoma.json___2', 'num': 2}),\n",
       " Document(page_content='Discussion.-In the absence of clinical evidence to the contrary, RET carriers with normal pretherapeutic basal calcitonin levels may forgo lymph node dissection.', metadata={'source': 'Ipsilateral Versus Bilateral Central Neck Lymph Node Dissection in Papillary Thyroid Carcinoma.json___3', 'num': 3}),\n",
       " Document(page_content='The usefulness of calcitonin thresholds to break down the block of carriers with increased calcitonin levels should be explored further.', metadata={'source': 'Ipsilateral Versus Bilateral Central Neck Lymph Node Dissection in Papillary Thyroid Carcinoma.json___4', 'num': 4}),\n",
       " Document(page_content='This article addresses the question regarding the extent of thyroidectomy ± neck dissection in patients with hereditary medullary thyroid cancer (MTC).', metadata={'source': 'Ipsilateral Versus Bilateral Central Neck Lymph Node Dissection in Papillary Thyroid Carcinoma.json___5', 'num': 5}),\n",
       " Document(page_content='The authors reviewed their large experience with familial MTC and demonstrated that patients with normal basal calcitonin levels can forego central neck dissection at the time of thyroidectomy as the', metadata={'source': 'Ipsilateral Versus Bilateral Central Neck Lymph Node Dissection in Papillary Thyroid Carcinoma.json___6', 'num': 6}),\n",
       " Document(page_content='incidence of lymph node (LN) metastases in this group was 0. In fact, they report that all carriers with LN metastases had basal calcitonin levels of >91 pg/mL.', metadata={'source': 'Ipsilateral Versus Bilateral Central Neck Lymph Node Dissection in Papillary Thyroid Carcinoma.json___7', 'num': 7}),\n",
       " Document(page_content='Although there is some additional risk (mainly of hypoparathyroidism) with performing central neck dissection over just thyroidectomy alone, it may be hard to not include a central neck dissection in', metadata={'source': 'Ipsilateral Versus Bilateral Central Neck Lymph Node Dissection in Papillary Thyroid Carcinoma.json___8', 'num': 8}),\n",
       " Document(page_content='the surgical approach to familial MTC, especially in older patients. Nevertheless, a normal preoperative calcitonin level would certainly enable a limited CND in patients with hereditary MTC.', metadata={'source': 'Ipsilateral Versus Bilateral Central Neck Lymph Node Dissection in Papillary Thyroid Carcinoma.json___9', 'num': 9}),\n",
       " Document(page_content='T Objective.-Many patients undergoing thyroidectomy for papillary thyroid carcinoma (PTC) have subclinical nodal disease at the time of surgery.', metadata={'source': 'Ipsilateral Versus Bilateral Central Neck Lymph Node Dissection in Papillary Thyroid Carcinoma.json___10', 'num': 10}),\n",
       " Document(page_content='Prophylactic bilateral central neck dissection (CND) is gaining acceptance in the treatment of PTC as studies have shown nodal disease increases the rate of local recurrence and may alter postsurgical', metadata={'source': 'Ipsilateral Versus Bilateral Central Neck Lymph Node Dissection in Papillary Thyroid Carcinoma.json___11', 'num': 11}),\n",
       " Document(page_content='radioactive iodine dosing. Given the potential complications of bilateral CND, we undertook a prospective study to determine the adequacy of prophylactic ipsilateral CND for PTC.', metadata={'source': 'Ipsilateral Versus Bilateral Central Neck Lymph Node Dissection in Papillary Thyroid Carcinoma.json___12', 'num': 12}),\n",
       " Document(page_content='Methods.-A total of 116 patients with PTC underwent total thyroidectomy and routine prophylactic CND at a tertiary referral center.', metadata={'source': 'Ipsilateral Versus Bilateral Central Neck Lymph Node Dissection in Papillary Thyroid Carcinoma.json___13', 'num': 13}),\n",
       " Document(page_content='Of these, 45 had right and left central neck lymph node basins submitted separately for pathologic examination. We examined the laterality of positive lymph nodes based on tumor location and size.', metadata={'source': 'Ipsilateral Versus Bilateral Central Neck Lymph Node Dissection in Papillary Thyroid Carcinoma.json___14', 'num': 14}),\n",
       " Document(page_content='Results.-Overall, positive lymph nodes were found in 45% of patients. Of the patients having a lateralized CND, 33% had ipsilateral positive nodes only, while 20% had bilateral positive nodes.', metadata={'source': 'Ipsilateral Versus Bilateral Central Neck Lymph Node Dissection in Papillary Thyroid Carcinoma.json___15', 'num': 15}),\n",
       " Document(page_content='None of the patients with tumor size #1 cm had bilateral positive lymph nodes compared with 31% of patients with tumors >1 cm (P ¼ 0.02).', metadata={'source': 'Ipsilateral Versus Bilateral Central Neck Lymph Node Dissection in Papillary Thyroid Carcinoma.json___16', 'num': 16}),\n",
       " Document(page_content='Multifocality did not affect lymph node metastasis in tumors #1 cm.', metadata={'source': 'Ipsilateral Versus Bilateral Central Neck Lymph Node Dissection in Papillary Thyroid Carcinoma.json___17', 'num': 17}),\n",
       " Document(page_content='Parathyroids were found in the pathology specimen of 34% of patients, 40% had parathyroids autotransplanted, 47% had temporary hypocalcemia, and 0% had permanent hypocalcemia.', metadata={'source': 'Ipsilateral Versus Bilateral Central Neck Lymph Node Dissection in Papillary Thyroid Carcinoma.json___18', 'num': 18}),\n",
       " Document(page_content='Rates of temporary and permanent recurrent laryngeal nerve injury were 5% and 0% respectively.\\nConclusions.', metadata={'source': 'Ipsilateral Versus Bilateral Central Neck Lymph Node Dissection in Papillary Thyroid Carcinoma.json___19', 'num': 19}),\n",
       " Document(page_content='-Ipsilateral CND appears to be sufficient in patients with tumors #1 cm. In tumors >1 cm, bilateral CND should be considered as these patients are more likely to have bilateral positive nodes.', metadata={'source': 'Ipsilateral Versus Bilateral Central Neck Lymph Node Dissection in Papillary Thyroid Carcinoma.json___20', 'num': 20}),\n",
       " Document(page_content='If tumor size is used as criteria for prophylactic CND, approximately one-third of patients can be spared a bilateral CND.', metadata={'source': 'Ipsilateral Versus Bilateral Central Neck Lymph Node Dissection in Papillary Thyroid Carcinoma.json___21', 'num': 21}),\n",
       " Document(page_content='The debate over whether to perform a routine prophylactic central neck dissection (CND) for papillary thyroid carcinoma (PTC) has heated up over the past year.', metadata={'source': 'Ipsilateral Versus Bilateral Central Neck Lymph Node Dissection in Papillary Thyroid Carcinoma.json___22', 'num': 22}),\n",
       " Document(page_content='Those in favor argue that lymph node metastases are found in central neck lymph nodes approximately 40% of the time and 25% of the time, even in the presence of papillary microcarcinoma.', metadata={'source': 'Ipsilateral Versus Bilateral Central Neck Lymph Node Dissection in Papillary Thyroid Carcinoma.json___23', 'num': 23}),\n",
       " Document(page_content='It has been well documented that there are increased risks associated with CND, particularly with regard to the parathyroid glands.', metadata={'source': 'Ipsilateral Versus Bilateral Central Neck Lymph Node Dissection in Papillary Thyroid Carcinoma.json___24', 'num': 24}),\n",
       " Document(page_content='This prospective study was undertaken to determine whether ipsilateral CND might be adequate for patients with PTC, with an ultimate goal of trying to achieve what is achieved with bilateral CND with', metadata={'source': 'Ipsilateral Versus Bilateral Central Neck Lymph Node Dissection in Papillary Thyroid Carcinoma.json___25', 'num': 25}),\n",
       " Document(page_content='the lower morbidity of a unilateral CND. The results suggest that, at least for papillary microcarcinoma, an ipsilateral CND may be adequate, though certainly additional data need to be accrued.', metadata={'source': 'Ipsilateral Versus Bilateral Central Neck Lymph Node Dissection in Papillary Thyroid Carcinoma.json___26', 'num': 26}),\n",
       " Document(page_content='Due to the additional risks involved in CND and the absence of strong data documenting a therapeutic advantage of CND, the inclusion of routine CND as a part of the surgical treatment of PTC should', metadata={'source': 'Ipsilateral Versus Bilateral Central Neck Lymph Node Dissection in Papillary Thyroid Carcinoma.json___27', 'num': 27}),\n",
       " Document(page_content='probably be restricted to experienced thyroid surgeons.', metadata={'source': 'Ipsilateral Versus Bilateral Central Neck Lymph Node Dissection in Papillary Thyroid Carcinoma.json___28', 'num': 28}),\n",
       " Document(page_content='Context.-Selective intraarterial calcium injection of the major pancreatic arteries with hepatic venous sampling [calcium arterial stimulation (CaStim)] has been used as a localizing tool for', metadata={'source': 'Ipsilateral Versus Bilateral Central Neck Lymph Node Dissection in Papillary Thyroid Carcinoma.json___29', 'num': 29}),\n",
       " Document(page_content='insulinomas at the National Institutes of Health (NIH) since 1989. The accuracy of this technique for localizing insulinomas was reported for all cases until 1996.', metadata={'source': 'Ipsilateral Versus Bilateral Central Neck Lymph Node Dissection in Papillary Thyroid Carcinoma.json___30', 'num': 30}),\n",
       " Document(page_content='Objectives.-The aim of the study was to assess the accuracy and track record of the CaStim over time and in the context of evolving technology and to review issues related to result interpretation and', metadata={'source': 'Ipsilateral Versus Bilateral Central Neck Lymph Node Dissection in Papillary Thyroid Carcinoma.json___31', 'num': 31}),\n",
       " Document(page_content='procedure complications. CaStim was the only invasive preoperative localization modality used at our center. Endoscopic ultrasound (US) was not studied.\\nChapter 7-Endocrine / 161', metadata={'source': 'Ipsilateral Versus Bilateral Central Neck Lymph Node Dissection in Papillary Thyroid Carcinoma.json___32', 'num': 32}),\n",
       " Document(page_content='Thyroid cancer accounts for 0.5-1.5% of all malignancies in the United States, and its incidence is increasing [1].', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___1', 'num': 1}),\n",
       " Document(page_content='The subtype of Papillary Thyroid Carcinoma (PTC) accounts for >85% of all thyroid cancer cases in geographical regions with sufficient iodine intake.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___2', 'num': 2}),\n",
       " Document(page_content='Patients diagnosed with papillary thyroid carcinoma generally have a good prognosis, which is why when complications do occur, the burden on the patient and the health system are all the more poignant', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___3', 'num': 3}),\n",
       " Document(page_content='. As a result of this, there is a general lack of evidence regarding the end stage morbidity and mortality of this condition.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___4', 'num': 4}),\n",
       " Document(page_content='Presentation of PTC may vary from a single solitary nodule or multiple co-existing nodules arising from separate foci in the thyroid gland.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___5', 'num': 5}),\n",
       " Document(page_content='Multifocality in thyroid cancer can be seen in 18-87% of cases [2]. Multifocality may be associated with either large tumours or small tumours [3,4].', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___6', 'num': 6}),\n",
       " Document(page_content='The majority of carcinomas are that of the microcarcinoma variety where individual tumours are <1cm, and may be present in a unilateral lobe or in the contralateral lobe as well.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___7', 'num': 7}),\n",
       " Document(page_content='Finding a thyroid nodule in one lobe, does not necessarily predict that both nodes are actively involved, however, bilaterality of nodules may occur in a broad distribution within populations, as it', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___8', 'num': 8}),\n",
       " Document(page_content='is seen in 13-71% of cases [4][5][6][7]. There remains uncertainty regarding the prognostic significance of multifocality in PTC.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___9', 'num': 9}),\n",
       " Document(page_content='The aims of this study were to perform a meta-analysis of the information surrounding multifocality in PTC and quantitatively assess multifocality and its association with features of disease', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___10', 'num': 10}),\n",
       " Document(page_content='progression, as well as assessing the patient demographics which are considered risk\\nM A N U S C R I P T A C C E P T E D', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___11', 'num': 11}),\n",
       " Document(page_content='factors to predispose an individual to develop multifocal lesions.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___12', 'num': 12}),\n",
       " Document(page_content='Quantitative data on the increased risk of multifocality may lead to more aggressive management of early stage disease and better patient outcomes.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___13', 'num': 13}),\n",
       " Document(page_content='We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [8].', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___14', 'num': 14}),\n",
       " Document(page_content='A systematic search of the databases MEDLINE (from 1950) and PubMed (from 1946) were used to identify relevant articles.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___15', 'num': 15}),\n",
       " Document(page_content=\"The search used the terms 'Thyroid Cancer' AND 'Multifocal' OR 'Multifocality', which were searched as text word and as exploded medical subject headings where possible.\", metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___16', 'num': 16}),\n",
       " Document(page_content='The reference lists of relevant articles were also searched for appropriate studies.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___17', 'num': 17}),\n",
       " Document(page_content='No language restrictions were used in either the search, however study selection was limited to English language studies. A search for unpublished literature was not performed.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___18', 'num': 18}),\n",
       " Document(page_content='We included studies that met the following inclusion criteria: 1) Studies were required to be retrospective in temporal direction; 2) Population and Cohort based studies or Cancer Registry studies; 3)', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___19', 'num': 19}),\n",
       " Document(page_content='English language studies; 4) 95% Confidence interval was reported; 5) Data was presented as an Odds Ratio or a Hazard Ratio; 6) Studies contained multifocality as a risk factor OR Prognostic Factor.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___20', 'num': 20}),\n",
       " Document(page_content='The data extraction was performed using a standardized data extraction form, collecting information on the publication year, study design, number of cases, number of controls, total sample size,', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___21', 'num': 21}),\n",
       " Document(page_content='temporal direction, population type, country, case control matching, number of adjusted variables, Odds Ratios (OR) or Hazard Ratios (HR), Confidence Intervals (CIs) or data used to calculate CIs.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___22', 'num': 22}),\n",
       " Document(page_content='Adjusted ratios were extracted in preference to non-adjusted ratios, however, where ratios were not provided, unadjusted ORs and HRs and CIs were calculated from available data.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___23', 'num': 23}),\n",
       " Document(page_content='Where more than one adjusted ratio was reported, we chose the ratio with the highest number of adjusted variables.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___24', 'num': 24}),\n",
       " Document(page_content='Where multiple risk estimates were available in the same study, for example due to the use of different comparator groups, they were included as separate risk estimates.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___25', 'num': 25}),\n",
       " Document(page_content='Pooled ORs, HRs and 95% CIs were calculated for cases of multifocality in thyroid cancer, taking into account various indicators of disease progression including common patient demographics, using a', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___26', 'num': 26}),\n",
       " Document(page_content='random effects model [9].', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___27', 'num': 27}),\n",
       " Document(page_content=\"We tested heterogeneity with Cochran's Q statistic, with P<0.10 indicating heterogeneity, and quantified the degree of heterogeneity using the I 2 statistic, which represents the percentage of the\", metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___28', 'num': 28}),\n",
       " Document(page_content='total variability across studies which is due to heterogeneity. I 2 values of 25, 50 and 75% corresponded to low, moderate and high degrees of heterogeneity respectively [10].', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___29', 'num': 29}),\n",
       " Document(page_content=\"We quantified publication bias using the Egger's regression model [11], with the effect of bias assessed using the fail-safe number method.\", metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___30', 'num': 30}),\n",
       " Document(page_content='The fail-safe number was the number of studies that we would need to have missed for our observed result to be nullified to statistical non-significance at the p<0.05 level.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___31', 'num': 31}),\n",
       " Document(page_content='Publication bias is generally\\nM A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 6', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___32', 'num': 32}),\n",
       " Document(page_content='regarded as a concern if the fail-safe number is less than 5n+10, with n being the number of studies included in the meta-analysis [12].', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___33', 'num': 33}),\n",
       " Document(page_content='All analyses were performed with Comprehensive Meta-analysis (version 2.0).', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___34', 'num': 34}),\n",
       " Document(page_content='ACCEPTED MANUSCRIPT 7\\n3. Results', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___35', 'num': 35}),\n",
       " Document(page_content='Using our electronic database search method we retrieved 751 references. 192 were deleted due to duplications.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___36', 'num': 36}),\n",
       " Document(page_content='A further 538 were deleted because they were not relevant to the topics of multifocality or thyroid cancer, or did not contain objective ORs or HRs.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___37', 'num': 37}),\n",
       " Document(page_content='After careful consideration of the inclusion and exclusion criteria for the review, a total of 21 articles were included in the final meta-analysis (Figure 1).', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___38', 'num': 38}),\n",
       " Document(page_content='To assess study quality we assessed all studies with respect to a finite number of variables including numerical description of the eligible participants included in the study, independent', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___39', 'num': 39}),\n",
       " Document(page_content='confirmation of multifocality, lymph node metastases, distant metastases and extra thyroidal extension and recurrence and reporting mode (either retrospective or prospective.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___40', 'num': 40}),\n",
       " Document(page_content='In our meta-analysis we have pooled data on the ORs and HRs for multifocality as an independent risk factor for thyroid cancer.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___41', 'num': 41}),\n",
       " Document(page_content='We compared the presence of multifocal disease with proportions of patients who have features of progression of their disease.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___42', 'num': 42}),\n",
       " Document(page_content='These included patients who had evidence of lymph node metastases (LNM), extra thyroidal extension (ETE), distant metastases (DM) and recurrence of disease.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___43', 'num': 43}),\n",
       " Document(page_content='Risk factors for multifocality were also assessed if objective quantitative data was available. These included age, gender and tumour size.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___44', 'num': 44}),\n",
       " Document(page_content='A total of 12 articles [13][14][15][16][17][18][19][20][21][22][23] were included in the analysis of multifocality as a risk factor for lymph node metastases.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___45', 'num': 45}),\n",
       " Document(page_content='This included a total of 43055 patients with thyroid cancer and 8657\\nM A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 8', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___46', 'num': 46}),\n",
       " Document(page_content='patients with evidence of multifocal disease.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___47', 'num': 47}),\n",
       " Document(page_content='The final odds ratio for the development of LNM in patients with multifocal disease was calculated to be 1.87 (95% CI=1.51-2.32) with I2 = 49.11 and p-value = 0.03 (Figure 2).', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___48', 'num': 48}),\n",
       " Document(page_content='A total of 14 studies [13, 14, 17-19, 21, 22, 24-27] were included in analysis of multifocality in patients with evidence of extra-thyroidal extension.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___49', 'num': 49}),\n",
       " Document(page_content='A total of 35189 patients with thyroid cancer, included 1664 patients with documented extra-thyroidal extension.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___50', 'num': 50}),\n",
       " Document(page_content='The final OR of patients with documented multifocality and extrathyroidal extension was 3.18 (95% CI = 0.69-14.71) with I2 = 95.62 and p-value <0.001 (Figure 3).', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___51', 'num': 51}),\n",
       " Document(page_content='33185 patients with thyroid carcinoma were included from 3 studies [4,21,24]. 157 patients from the above population had distant metastases.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___52', 'num': 52}),\n",
       " Document(page_content='The OR calculated for patients with distant metastases with multifocality was 1.00 (95% Ci = 0.39-2.56) with I2 = 92.11 and p-value <0.001 (Figure 4).', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___53', 'num': 53}),\n",
       " Document(page_content='5 studies [15,25,[28][29][30] consisted of 178550 patients with thyroid cancer. 1498 of these patients had recurrences. Data for recurrences took into account HRs instead of ORs. The calculated HR', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___54', 'num': 54}),\n",
       " Document(page_content='for recurrences in the presence of documented multifocality was 2.81 (95% CI = 1.07-7.36) with I2 = 95.85 and p-value < 0.001 (Figure 5).', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___55', 'num': 55}),\n",
       " Document(page_content='4 studies [4,21,31,32] contained data for patients of >45 years old. Included in the analysis were 35810 patients who had thyroid cancer.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___56', 'num': 56}),\n",
       " Document(page_content='The OR calculated for multifocality in patients with thyroid cancer who are >45 years old is 0.86 (95% CI = 0.57-1.28) with I2 =76.52 and p-value = 0.005 (Figure 6).', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___57', 'num': 57}),\n",
       " Document(page_content='5 studies [4,21,26,30,32] contained data on the male gender. OR for male gender with multifocality is 0.98 (95% CI = 0.68-1.42) with I2 = 69.78 with p-value = 0.01 (Figure 7).', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___58', 'num': 58}),\n",
       " Document(page_content='A total of 3 studies [4,26,32] looked at tumour Size, specifically of tumours >1cm. The OR for tumour size and multifocality is 2.75 (95% CI = 1.95-3.89) with I2 = 0.00 and p-value = 0.88 (Figure 8).', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___59', 'num': 59}),\n",
       " Document(page_content='ACCEPTED MANUSCRIPT 10', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___60', 'num': 60}),\n",
       " Document(page_content='The current pattern of practice in the management of the early stages of thyroid cancer varies widely between clinicians and treatment centres [33].', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___61', 'num': 61}),\n",
       " Document(page_content='The reasons for this include a lack of randomised controlled trials, temporal changes to presentation and practice, and conflicting reports on treatment modalities.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___62', 'num': 62}),\n",
       " Document(page_content='Prior to this review, there has not been a quantitative analysis of the association between multifocality and disease progression.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___63', 'num': 63}),\n",
       " Document(page_content='The prognostic importance of multifocal tumour growth has been a controversial topic, however, it has always been considered a poor prognostic factor for patients with thyroid carcinoma.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___64', 'num': 64}),\n",
       " Document(page_content='In particular, PTC has been of particular interest in recent years due to the finding that patients with traditional PTC may also have other smaller foci of micro carcinomas within thyroid tissue.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___65', 'num': 65}),\n",
       " Document(page_content='This bears increasing relevance to patients in a younger age group whose smaller undetectable micro carcinomas have yet to develop into PTC.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___66', 'num': 66}),\n",
       " Document(page_content='It is currently not known whether multifocality in thyroid carcinoma may be a result of true multicentricity (which does not necessarily represent progress of disease as a function of time) or intra-', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___67', 'num': 67}),\n",
       " Document(page_content='thyroidal metastases from a single malignant focus (an indication of progression of disease).', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___68', 'num': 68}),\n",
       " Document(page_content='A number of autopsy studies in Finland have reported a large number of undiagnosed PTC in patients dying of unrelated causes [34].', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___69', 'num': 69}),\n",
       " Document(page_content='The finding of the autopsy studies may favour a multicentric aetiology to the carcinomas, however findings from this meta-analysis support a progressive view where worsening of multifocality is', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___70', 'num': 70}),\n",
       " Document(page_content='associated with features of disease progression.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___71', 'num': 71}),\n",
       " Document(page_content='Firstly, our analysis succeeded in demonstrating a high association between multifocality and lymph node metastases, extra thyroidal extension, and tumour size. All of which are known', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___72', 'num': 72}),\n",
       " Document(page_content='M A N U S C R I P T A C C E P T E D', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___73', 'num': 73}),\n",
       " Document(page_content='factors of disease progression. Tumour size at time of diagnosis may also be considered to be a risk factor for the development of multifocality in PTC (See Figures 1,2, and 8).', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___74', 'num': 74}),\n",
       " Document(page_content='Tumour size has been a topic a interest in recent years. In particular, microcarcinomas (tumours <1cm in size) have been previously shown to be associated with multifocality [26].', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___75', 'num': 75}),\n",
       " Document(page_content='Less information is known about multifocality in larger, more advanced stage tumours. Our current research therefore looked specifically at tumour sizes >1cm.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___76', 'num': 76}),\n",
       " Document(page_content='Our analysis showed a significant correlation between tumour size and multifocality, suggesting that multifocality is an indicator of disease progression (Figure 8).', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___77', 'num': 77}),\n",
       " Document(page_content='The current study demonstrated that multifocality is also associated with an increased risk of disease recurrence.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___78', 'num': 78}),\n",
       " Document(page_content='The mechanisms for this may vary, and are not limited to the possibilities of left over thyroid tissue from total thyroidectomies and surrounding ectopic sites of congenital thyroid tissue.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___79', 'num': 79}),\n",
       " Document(page_content='Irrespective of the reasons, the increased risk of recurrence would necessitate the use of Radioactive Iodine (RAI) treatment in the definitive management of recurrences.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___80', 'num': 80}),\n",
       " Document(page_content='Early intervention and RAI treatment may be necessary in such patients.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___81', 'num': 81}),\n",
       " Document(page_content='Age is included as a risk factor in multiple scoring systems, including TNM, AMES, AGES and MACIS [35].', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___82', 'num': 82}),\n",
       " Document(page_content='Our study showed that there was not a significant increase in association between increased age and multifocality.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___83', 'num': 83}),\n",
       " Document(page_content='Only 1 of the 4 studies with consistent variables and odds ratios showed an increased risk of multifocality in patients >45 years old [21].', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___84', 'num': 84}),\n",
       " Document(page_content='The prevalence of PTC is known to be skewed toward the female gender.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___85', 'num': 85}),\n",
       " Document(page_content='In our analysis of multifocality, we looked specifically at studies which involved a male population group in order to determine whether the male gender had a different risk of developing', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___86', 'num': 86}),\n",
       " Document(page_content='multifocality. The studies showed an almost equivocal distribution between the sexes with only a slight skew against an association with the male gender (OR=0.98) (Figure 7).', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___87', 'num': 87}),\n",
       " Document(page_content='The difficulty obtaining good data on mortality is likely due to the good prognosis of thyroid carcinoma. There are no randomised controlled trials of the current data.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___88', 'num': 88}),\n",
       " Document(page_content='Future studies should include a more detailed analysis into the extent of multifocality including number of foci as well as clonal origin of foci.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___89', 'num': 89}),\n",
       " Document(page_content='Although not specifically investigated in the current study, complications arising from more aggressive surgical management must be taken into consideration when using multifocality as a prognostic', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___90', 'num': 90}),\n",
       " Document(page_content='factor.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___91', 'num': 91}),\n",
       " Document(page_content='A number of studies have suggested that due to a higher complication rates of more aggressive surgical options such as total thyroidectomy and central neck dissections, hemi thyroidectomy should be', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___92', 'num': 92}),\n",
       " Document(page_content='considered first line treatment for unilateral multifocal disease [36,37].', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___93', 'num': 93}),\n",
       " Document(page_content='Further research is warranted to compare the risks of operative complications with the risk of disease progression or recurrence.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___94', 'num': 94}),\n",
       " Document(page_content='In conclusion, we support the current treatment of total thyroidectomy for patients who have multi focal disease.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___95', 'num': 95}),\n",
       " Document(page_content='The high association with features of disease progression such as LNMs, ETE, and Tumour Size, early surgical intervention may also be indicated.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___96', 'num': 96}),\n",
       " Document(page_content='Given the high association between multifocal disease and tumour recurrence, early treatment of such patients with radioactive iodine may also be beneficial.         -Patients with multifocal disease', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___97', 'num': 97}),\n",
       " Document(page_content='are more likely to have extrathyroidal extension.\\nFigure Legends\\n-Patients with multifocal disease are at high risk for progression of disease.', metadata={'source': 'Multifocality as a prognostic factor in thyroid cancer_ A meta-analysis.json___98', 'num': 98}),\n",
       " Document(page_content='The incidence of thyroid cancer has nearly tripled in the last four decades, from 4.56 to 14.42 per 10 0,0 0 0 individuals.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___1', 'num': 1}),\n",
       " Document(page_content='1 The national burden of thyroid cancer in the United States, both in terms of the number of affected individuals and the absolute economic cost, is projected to continue to rise in the future.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___2', 'num': 2}),\n",
       " Document(page_content='[2][3][4] Although thyroid cancer is associated with a high survival rate, individuals diagnosed with thyroid cancer experience physical, mental, and financial challenges as a consequence of diagnosis', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___3', 'num': 3}),\n",
       " Document(page_content='and treatment. [5][6][7] This physical and emotional burden is often experienced throughout many decades attributable to the excellent survival.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___4', 'num': 4}),\n",
       " Document(page_content=\"[8][9][10] A better understanding of health-related quality of life (HRQOL) from patients' perspectives is needed to correctly characterize the degree of physical and psychologic distress from thyroid\", metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___5', 'num': 5}),\n",
       " Document(page_content='cancer.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___6', 'num': 6}),\n",
       " Document(page_content='Few studies that describe HRQOL in thyroid cancer survivors have compared patient-reported outcomes (PROs) with US normative data or PROs from other types of cancers.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___7', 'num': 7}),\n",
       " Document(page_content='11 Earlier studies have indicated the need for a more concise yet valid questionnaire to ascertain HRQOL in the thyroid cancer survivor population.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___8', 'num': 8}),\n",
       " Document(page_content='5,8 , 12 We assessed quality of life in thyroid cancer survivors using the Patient-Reported Outcomes Measurement Information System (PROMIS) 29-item profile (funded by the US National Institutes of', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___9', 'num': 9}),\n",
       " Document(page_content='Health), an instrument that enabled us to', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___10', 'num': 10}),\n",
       " Document(page_content='JID: YMSY [m5G; August 24, 2018;15:29 ]   compare PROs against US normative data and other disease cohorts.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___11', 'num': 11}),\n",
       " Document(page_content='13,14 We hypothesized that the surveyed thyroid cancer survivors would report HRQOL poorer than that of the US general population but similar to that of individuals with other cancers.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___12', 'num': 12}),\n",
       " Document(page_content='We designed a survey to assess demographics, diagnosis history, clinical characteristics, treatment history, adverse effects of treatment, and financial characteristics among thyroid cancer survivors', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___13', 'num': 13}),\n",
       " Document(page_content=\"in collaboration with the Thyroid Cancer Survivors' Association, Inc (ThyCa, Olney, MD).\", metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___14', 'num': 14}),\n",
       " Document(page_content='This survey was based on a quality-oflife study conducted in multiple endocrine neoplasia patients and is described in detail elsewhere.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___15', 'num': 15}),\n",
       " Document(page_content='15 The survey was piloted by 10 individuals with thyroid cancer plus four clinicians, and survey content was adjusted based on their feedback.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___16', 'num': 16}),\n",
       " Document(page_content='The PROMIS 29-item profile measure was used to assess HRQOL.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___17', 'num': 17}),\n",
       " Document(page_content='PROMIS-29 measures dimensions of mental, physical, and social health across seven domains (depression, anxiety, pain interference, physical function, fatigue, satisfaction with social role', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___18', 'num': 18}),\n",
       " Document(page_content='participation [ie, social function], and sleep disturbance). PROMIS measures have been used in a wide range of clinical settings and have been demonstrated to be reliable and valid.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___19', 'num': 19}),\n",
       " Document(page_content='[16][17][18] PROMIS-29 has been demonstrated to be valid in several chronic conditions.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___20', 'num': 20}),\n",
       " Document(page_content='19,20 The PROMIS metric is the T-score, where a score of 50 represents the mean response for the general US population (standard deviation = 10).', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___21', 'num': 21}),\n",
       " Document(page_content='21 Worse HRQOL is indicated by higher scores in the domains of anxiety, depression, fatigue, pain interference, and sleep disturbance, and, conversely, lower scores in the physical functioning and', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___22', 'num': 22}),\n",
       " Document(page_content='social function domains.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___23', 'num': 23}),\n",
       " Document(page_content='PROMIS measures are based on responses from the US general population, and it is possible to make statistical comparisons between responses from thyroid cancer patients and expected responses from the', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___24', 'num': 24}),\n",
       " Document(page_content='general US population for each domain.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___25', 'num': 25}),\n",
       " Document(page_content='Furthermore, PROMIS was developed to measure PROs and function and aspects of HRQOL across a variety of chronic diseases and conditions and is not disease specific in its approach.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___26', 'num': 26}),\n",
       " Document(page_content='The diseaseagnostic nature of PROMIS allows the comparison of PROs across a variety of chronic medical conditions within the US population.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___27', 'num': 27}),\n",
       " Document(page_content='Adults with a history of thyroid cancer were recruited online through ThyCa for a six-month study period (January 2017-June 2017).', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___28', 'num': 28}),\n",
       " Document(page_content='The ThyCa organization has approximately 70,0 0 0 members in various stages of thyroid cancer treatment.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___29', 'num': 29}),\n",
       " Document(page_content='A survey uniform resource locator was distributed online via the ThyCa website, email newsletter, and social media pages (Facebook and Twitter).', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___30', 'num': 30}),\n",
       " Document(page_content='The survey was entirely online; no paper surveys were distributed.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___31', 'num': 31}),\n",
       " Document(page_content='Study eligibility criteria included the following: a diagnosis of thyroid cancer, residency in the United States, and age 18-89 years at the time of survey participation.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___32', 'num': 32}),\n",
       " Document(page_content='Participants who reported that they had not been diagnosed with thyroid cancer by a physician were excluded from this study.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___33', 'num': 33}),\n",
       " Document(page_content='The cohort of respondents to this survey has been designated the ThyCa Cohort.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___34', 'num': 34}),\n",
       " Document(page_content='Study participants who completed an electronic consent took a two-part questionnaire online through REDCap (Nashville, TN), a secure, Web-based platform for collecting and managing survey data for', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___35', 'num': 35}),\n",
       " Document(page_content='research purposes. 22 Participants self-reported their clinical characteristics, including stage of cancer, if known.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___36', 'num': 36}),\n",
       " Document(page_content='Participants were excluded from our analysis if they did not complete both parts of the two-part questionnaire.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___37', 'num': 37}),\n",
       " Document(page_content='Responses were recorded anonymously by assigning participants a unique subject identifier code in the REDCap database. The Northwestern University Institutional Review Board approved this study.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___38', 'num': 38}),\n",
       " Document(page_content='T-scores corresponding to each PROMIS-29 domain were generated using the HealthMeasures Scoring Service ( www. healthmeasures.net ) for all respondents.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___39', 'num': 39}),\n",
       " Document(page_content='PROMIS T-scores were compared with US normative data using a one-sample T-test. PROMIS T-scores from short forms completed by patients with breast', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___40', 'num': 40}),\n",
       " Document(page_content='( n = 1,588), prostate ( n = 1,140), uterine ( n = 388), cervi- cal ( n = 141), colorectal ( n = 890), non-Hodgkin lymphoma ([NHL] n = 443', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___41', 'num': 41}),\n",
       " Document(page_content='), and lung ( n = 694) cancers were obtained from the literature.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___42', 'num': 42}),\n",
       " Document(page_content=\"23 These patients were between the ages of 21-89 years and recruited through the National Cancer Institute's Surveillance, Epidemiology, and End Results Program at 6-13 months after the diagnosis of\", metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___43', 'num': 43}),\n",
       " Document(page_content='their cancer. [23][24][25] These cancer cohorts represent a diverse group of patients with various stages of cancer and at varying cancer treatment stages (active, cured, or in remission).', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___44', 'num': 44}),\n",
       " Document(page_content='These individuals took a self-administered paper PROMIS survey received via mailing. These data were compared with the T-scores of our thyroid cancer cohort using the Wilcoxon signed-rank test.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___45', 'num': 45}),\n",
       " Document(page_content='Based on earlier PROMIS validation studies in cancer, we considered a difference of three points or greater to indicate a clinically meaningful difference.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___46', 'num': 46}),\n",
       " Document(page_content='26 The Bonferroni-Holm method was used to correct for multiple comparisons. Data analysis was conducted in SAS, Version 9.4 (SAS Institute, Cary, NC).', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___47', 'num': 47}),\n",
       " Document(page_content='During the six-month study period, January 2017-June 2017, the thyroid cancer quality of life survey uniform resource locator was accessed 3,174 times.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___48', 'num': 48}),\n",
       " Document(page_content='A total of 1,978 individuals consented to take the survey, and 1,923 individuals completed both components of the survey (clinical conditions and factors survey and the PROMIS-29 instrument).', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___49', 'num': 49}),\n",
       " Document(page_content='Of those complete surveys, 1,743 (55% of those who accessed the survey, 91% of completed surveys) were from the United States and, therefore, only these respondents were included in the final analysis', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___50', 'num': 50}),\n",
       " Document(page_content='.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___51', 'num': 51}),\n",
       " Document(page_content='The sample characteristics of the final cohort of 1,743 US adult respondents are reported in the Table 1 . The majority of participants were female (88%) and white (95%    8 ).', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___52', 'num': 52}),\n",
       " Document(page_content='Surveyed thyroid cancer survivors reported statistically significantly worse scores for anxiety, depression, fatigue, and sleep disturbance than NHL, breast, colorectal, uterine, and prostate cancers', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___53', 'num': 53}),\n",
       " Document(page_content='( P < .01). Surveyed individuals with thyroid cancer also reported worse social functioning scores than all cancers we compared against, except for lung cancer (48.1 vs 44.6, P < .01).', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___54', 'num': 54}),\n",
       " Document(page_content='Surveyed individuals with thyroid cancer reported less pain than all other cancers, except for uterine and prostate cancers ( P < .01).', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___55', 'num': 55}),\n",
       " Document(page_content='They also reported statistically significantly greater physical functioning than all cancers except for prostate cancer ( P < .01).', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___56', 'num': 56}),\n",
       " Document(page_content='Thyroid cancer is projected to be the third most common cancer among women by 2019.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___57', 'num': 57}),\n",
       " Document(page_content='The PROMIS-29 was designed to facilitate comparisons among various clinical populations, and it has been used to measure HRQOL among patients with several other types of cancer.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___58', 'num': 58}),\n",
       " Document(page_content='14,27 Therefore, we were able to compare our results with those from patients with other types of cancer, including breast, prostate, cervical, colorectal, uterine, lung, and NHL.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___59', 'num': 59}),\n",
       " Document(page_content='PRO data are essential because they enable providers to understand HRQOL from the perspective of patients.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___60', 'num': 60}),\n",
       " Document(page_content='Herein, we found that surveyed thyroid cancer patients reported statistically significantly worse quality of life in all seven PROMIS-29 domains and clinically significantly worse HRQOL in the domains', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___61', 'num': 61}),\n",
       " Document(page_content='of anxiety, fatigue, and sleep disturbance compared with US normative data ( Fig 1 ).', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___62', 'num': 62}),\n",
       " Document(page_content='Surveyed thyroid cancer survivors also reported statistically significantly worse HRQOL compared with other cancers in several domains, including anxiety, depression, fatigue, sleep disturbance, and', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___63', 'num': 63}),\n",
       " Document(page_content='social functioning ( Figs 2345678). Many of these statistically significant differences were also likely clinically significant.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___64', 'num': 64}),\n",
       " Document(page_content='We also found that individuals with thyroid cancer surveyed in this study reported greater physical functioning and less pain than survivors of several other cancers.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___65', 'num': 65}),\n",
       " Document(page_content='Although thyroid cancer may have higher survival rates and be less physically painful than other cancers, thyroid cancer survivors may suffer from significant psychologic and emotional distress.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___66', 'num': 66}),\n",
       " Document(page_content='This conclusion is consistent with the study by Applewhite et al, 28 who found that HRQOL in thyroid cancer patients is similar to, or worse than, that of patients with colon, glioma, breast, and', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___67', 'num': 67}),\n",
       " Document(page_content='gynecologic cancers, using the QOL-Cancer Survivor instrument to measure HRQOL in cancer patients.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___68', 'num': 68}),\n",
       " Document(page_content='In addition, other studies have also shown that a history of thyroid cancer is associated with increased anxiety and depression among patients.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___69', 'num': 69}),\n",
       " Document(page_content='[5][6][7] The finding of substantial psychologic and emotional distress among thyroid cancer survivors is notable because the vast majority of patients  live on to face the consequences of their', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___70', 'num': 70}),\n",
       " Document(page_content='illness and the treatments they received for many decades after diagnosis.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___71', 'num': 71}),\n",
       " Document(page_content='5,9 , 10 However, because thyroid cancer is more common in women and affects individuals at a younger age, we must recognize that age and sex are potential confounding factors that may drive', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___72', 'num': 72}),\n",
       " Document(page_content='variations in HRQOL among cancer types. Further work must aim to understand which factors drive HRQOL variations among these groups.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___73', 'num': 73}),\n",
       " Document(page_content='A strength of our study was the large sample size.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___74', 'num': 74}),\n",
       " Document(page_content='By distributing our survey through a thyroid cancer support group (ThyCa), we could reach a large population of individuals diagnosed with thyroid cancer.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___75', 'num': 75}),\n",
       " Document(page_content='To our knowledge, our sample size is one of the largest among studies of this kind.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___76', 'num': 76}),\n",
       " Document(page_content='10 A second strength of our study is that it comprises a group of participants that reflects the general population of US thyroid cancer survivors in several ways ( Table 1 ).', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___77', 'num': 77}),\n",
       " Document(page_content='Our sample includes individuals who represent all the major types and stages of thyroid cancer, as well as the full spectrum of available treatments.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___78', 'num': 78}),\n",
       " Document(page_content='A total of 85% of our sample had papillary thyroid cancer, and approximately 5% of our sample had more aggressive types of thyroid cancer (medullary and anaplastic), which is consistent with the US', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___79', 'num': 79}),\n",
       " Document(page_content=\"thyroid cancer diagnosis trends. 29 Our sample's mean age at diagnosis was 44 years, which closely approximates the age of diagnosis found in the thyroid cancer survivor population.\", metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___80', 'num': 80}),\n",
       " Document(page_content='1 Furthermore, our sample approximates the majority-female population of thyroid cancer survivors, as the incidence of thyroid cancer among women is three times higher than in men.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___81', 'num': 81}),\n",
       " Document(page_content='29 However, our sample was mostly white (95%) and does not reflect the true racial diversity of this disease. 30 Most patients diagnosed with thyroid cancer have stage I disease.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___82', 'num': 82}),\n",
       " Document(page_content='Although 30% of our sample self-reported having stage I cancer, 28% reported either not knowing or not being staged.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___83', 'num': 83}),\n",
       " Document(page_content='It is possible that some or most of the 28% had stage I disease, but it is also possible that our sample over-represents later-stage patients who would likely score worse in several HRQOL domains.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___84', 'num': 84}),\n",
       " Document(page_content='A limitation of our study is that our recruitment method introduced the possibility of selection bias.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___85', 'num': 85}),\n",
       " Document(page_content='To complete the survey, participants needed access to the internet and the ability to comprehend the English language. Members of a support group are likely different than other clinical samples.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___86', 'num': 86}),\n",
       " Document(page_content='Because they have joined such a group, they may be more committed to issues with respect to their condition and may have different coping strategies and perceptions about their disease compared with', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___87', 'num': 87}),\n",
       " Document(page_content='individuals who do not participate in support groups.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___88', 'num': 88}),\n",
       " Document(page_content='A single study has shown that cancer support group members often use more active coping mechanisms and possess a greater sense of control but report more anxiety and distress about their disease.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___89', 'num': 89}),\n",
       " Document(page_content='31 They may also not be representative regarding racial, sex, and socioeconomic characteristics.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___90', 'num': 90}),\n",
       " Document(page_content='Thus, because of the possibility of selection bias attributable to our recruitment method, individuals in our cohort may be more severely affected by their thyroid cancer diagnosis and therefore', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___91', 'num': 91}),\n",
       " Document(page_content='report worse HRQOL scores than those who declined to take this survey.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___92', 'num': 92}),\n",
       " Document(page_content='In addition, because this study was conducted via online survey, it precluded us from verifying the self-reported clinical characteristics of our participants, including the pathologic findings,', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___93', 'num': 93}),\n",
       " Document(page_content='laboratory results, or stage of cancer. This methodology was necessary to obtain a snapshot of the HRQOL of the largest number of US thyroid cancer survivors.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___94', 'num': 94}),\n",
       " Document(page_content='The psychometric characteristics of PROMIS-29 in thyroid cancer have yet to be fully characterized.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___95', 'num': 95}),\n",
       " Document(page_content='Thus, further research is needed to explore the degree to which this measure fully captures the range of HRQOL deficits experienced by people with this disease.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___96', 'num': 96}),\n",
       " Document(page_content='The importance of HRQOL among thyroid cancer survivors should not be obscured by the relatively high survival rate of thyroid cancer compared with other cancers.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___97', 'num': 97}),\n",
       " Document(page_content='The five-year survi val rate of thyroid cancer patients (98.2%) is higher than other cancers compared in this study, excluding prostate cancer.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___98', 'num': 98}),\n",
       " Document(page_content='30,32 It seems intuitive, therefore, that a diagnosis of thyroid cancer would be less burdensome than that of more aggressive cancers.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___99', 'num': 99}),\n",
       " Document(page_content='However, our results demonstrate that the surveyed thyroid cancer survivors may be encumbered with greater psychologic and social burdens than survivors of cancers that, in most cases, have a worse', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___100', 'num': 100}),\n",
       " Document(page_content='prognosis. Further research must aim to understand the factors that drive poor HRQOL scores in US thyroid cancer survivors and examine how HRQOL changes with time since diagnosis and treatment.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___101', 'num': 101}),\n",
       " Document(page_content='Thyroid cancer survivors live many years from diagnosis and treatment.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___102', 'num': 102}),\n",
       " Document(page_content='As individuals move further from diagnosis, treatment side effects, such as scars and voice changes may diminish, yet social and psychologic burden from surveillance and fear of recurrence may persist', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___103', 'num': 103}),\n",
       " Document(page_content='.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___104', 'num': 104}),\n",
       " Document(page_content='The survivorship phase of thyroid cancer survivors is dynamic, and further studies must aim to understand whether and how HRQOL changes over time and which factors drive HRQOL at different time points', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___105', 'num': 105}),\n",
       " Document(page_content='.\\nIt is essential to develop a more complete understanding of quality of life in the growing population of cancer survivors. The HRQOL burden of thyroid cancer should not be underestimated.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___106', 'num': 106}),\n",
       " Document(page_content='Please cite this article as: S.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___107', 'num': 107}),\n",
       " Document(page_content='Goswami et al., Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data, Surgery (2018), https://doi.org/10.1016/j.surg.2018.06.042', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___108', 'num': 108}),\n",
       " Document(page_content='JID: YMSY [m5G; August 24, 2018;15:29 ]   This study highlights the need for further characterization of HRQOL in this population.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___109', 'num': 109}),\n",
       " Document(page_content='Further studies must aim to understand the factors that drive HRQOL in thyroid cancer survivors to ensure adequate information and support is provided to this enlarging population.', metadata={'source': 'Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.json___110', 'num': 110}),\n",
       " Document(page_content='Objective.dTo provide comprehensive clinicopathologic data, comparing the growth pattern and metastatic behavior of papillary thyroid cancer between children and adolescents.', metadata={'source': 'Papillary Thyroid Cancer in Children and Adolescents Does Not Differ in Growth Pattern and Metastatic Behavior.json___1', 'num': 1}),\n",
       " Document(page_content='Study Design.dThis clinicopathologic investigation included 83 consecutive patients ages 6 to 18 years operated on for papillary thyroid cancer at a tertiary referral center in Germany (1994Germany (', metadata={'source': 'Papillary Thyroid Cancer in Children and Adolescents Does Not Differ in Growth Pattern and Metastatic Behavior.json___2', 'num': 2}),\n",
       " Document(page_content='to 2009)).', metadata={'source': 'Papillary Thyroid Cancer in Children and Adolescents Does Not Differ in Growth Pattern and Metastatic Behavior.json___3', 'num': 3}),\n",
       " Document(page_content='Results.dThere was no difference in sex distribution, re-operation rate, medical history of external radiation, multifocal tumor growth, number of thyroid cancers, extrathyroidal tumor growth, lymph', metadata={'source': 'Papillary Thyroid Cancer in Children and Adolescents Does Not Differ in Growth Pattern and Metastatic Behavior.json___4', 'num': 4}),\n",
       " Document(page_content='node metastasis, numbers of involved and removed nodes or distant metastasis among patients ages 6 to 11, 12 to 15, and 16 to 18 years.', metadata={'source': 'Papillary Thyroid Cancer in Children and Adolescents Does Not Differ in Growth Pattern and Metastatic Behavior.json___5', 'num': 5}),\n",
       " Document(page_content='Patients with extrathyroidal growth, unlike those with intrathyroidal growth, had larger tumors, especially in the oldest age group (means of 20, 26, and 44 mm for patients ages 6 to 11, 12 to 15, and', metadata={'source': 'Papillary Thyroid Cancer in Children and Adolescents Does Not Differ in Growth Pattern and Metastatic Behavior.json___6', 'num': 6}),\n",
       " Document(page_content='16 to 18 years; P ¼.015); the statistical significance was lost after correction for multiple testing.', metadata={'source': 'Papillary Thyroid Cancer in Children and Adolescents Does Not Differ in Growth Pattern and Metastatic Behavior.json___7', 'num': 7}),\n",
       " Document(page_content='Conclusion.dHaving comparable extent of disease, children should not undergo less extensive neck operations than adolescents for papillary thyroid cancer.', metadata={'source': 'Papillary Thyroid Cancer in Children and Adolescents Does Not Differ in Growth Pattern and Metastatic Behavior.json___8', 'num': 8}),\n",
       " Document(page_content='This report, like so many others, reminds us that children are not small adults. This is true when it comes to infrequent diseases such as papillary thyroid cancer.', metadata={'source': 'Papillary Thyroid Cancer in Children and Adolescents Does Not Differ in Growth Pattern and Metastatic Behavior.json___9', 'num': 9}),\n",
       " Document(page_content='Thyroid cancer is uncommon in childhood and adolescence with an estimated frequency of 0.7 per 1 million.', metadata={'source': 'Papillary Thyroid Cancer in Children and Adolescents Does Not Differ in Growth Pattern and Metastatic Behavior.json___10', 'num': 10}),\n",
       " Document(page_content='If someone in the pediatric population does get thyroid cancer, it is most likely a papillary thyroid malignancy.', metadata={'source': 'Papillary Thyroid Cancer in Children and Adolescents Does Not Differ in Growth Pattern and Metastatic Behavior.json___11', 'num': 11}),\n",
       " Document(page_content='If you look at a comparison between children/adolescents and adults, the former group has significantly larger papillary thyroid cancers (usually at least 50% larger in various series compared with', metadata={'source': 'Papillary Thyroid Cancer in Children and Adolescents Does Not Differ in Growth Pattern and Metastatic Behavior.json___12', 'num': 12}),\n",
       " Document(page_content='adults) and more likely spread to regional lymph nodes and distant organs by the time a diagnosis is made.', metadata={'source': 'Papillary Thyroid Cancer in Children and Adolescents Does Not Differ in Growth Pattern and Metastatic Behavior.json___13', 'num': 13}),\n",
       " Document(page_content='It has also been suggested that there are higher recurrence rates of cervical lymph node metastases in children versus adults.', metadata={'source': 'Papillary Thyroid Cancer in Children and Adolescents Does Not Differ in Growth Pattern and Metastatic Behavior.json___14', 'num': 14}),\n",
       " Document(page_content='Despite these apparently adverse factors, papillary thyroid cancer has a better prognosis in children than in adults, with 98%, 97%, and 91% of pediatric patients surviving 5, 15, and 30 years,', metadata={'source': 'Papillary Thyroid Cancer in Children and Adolescents Does Not Differ in Growth Pattern and Metastatic Behavior.json___15', 'num': 15}),\n",
       " Document(page_content='respectively.', metadata={'source': 'Papillary Thyroid Cancer in Children and Adolescents Does Not Differ in Growth Pattern and Metastatic Behavior.json___16', 'num': 16}),\n",
       " Document(page_content='Part of this added survival could be because therapeutic doses of radioactive iodine may more effectively eradicate malignant thyroid tissue since children have more active iodine metabolism.', metadata={'source': 'Papillary Thyroid Cancer in Children and Adolescents Does Not Differ in Growth Pattern and Metastatic Behavior.json___17', 'num': 17}),\n",
       " Document(page_content='Unfortunately, there is not a great deal written about papillary thyroid cancer in children and adolescents, most likely because of its relative infrequency.', metadata={'source': 'Papillary Thyroid Cancer in Children and Adolescents Does Not Differ in Growth Pattern and Metastatic Behavior.json___18', 'num': 18}),\n",
       " Document(page_content='The report of Machens et al from Germany adds a lot to our understanding about this disorder.', metadata={'source': 'Papillary Thyroid Cancer in Children and Adolescents Does Not Differ in Growth Pattern and Metastatic Behavior.json___19', 'num': 19}),\n",
       " Document(page_content='The center from which this study is reported is well known throughout Europe for the care of children with various thyroid diseases, including cancer.', metadata={'source': 'Papillary Thyroid Cancer in Children and Adolescents Does Not Differ in Growth Pattern and Metastatic Behavior.json___20', 'num': 20}),\n",
       " Document(page_content='The investigators were able to look at the records of 83', metadata={'source': 'Papillary Thyroid Cancer in Children and Adolescents Does Not Differ in Growth Pattern and Metastatic Behavior.json___21', 'num': 21}),\n",
       " Document(page_content='Chapter 16eOncology / 485 consecutive patients aged 18 years and younger who were operated on for papillary thyroid cancer over a 15-year period between 1994 and 2009.', metadata={'source': 'Papillary Thyroid Cancer in Children and Adolescents Does Not Differ in Growth Pattern and Metastatic Behavior.json___22', 'num': 22}),\n",
       " Document(page_content='Their observations show that in young children, the tumor more frequently breached the thyroid capsule, presumably because thyroid volumes are smaller than those in adults.', metadata={'source': 'Papillary Thyroid Cancer in Children and Adolescents Does Not Differ in Growth Pattern and Metastatic Behavior.json___23', 'num': 23}),\n",
       " Document(page_content='Almost all children and adolescents harbored lymph node metastases in addition to extrathyroidal tumor extension.', metadata={'source': 'Papillary Thyroid Cancer in Children and Adolescents Does Not Differ in Growth Pattern and Metastatic Behavior.json___24', 'num': 24}),\n",
       " Document(page_content='As often as not, these regional metastases were the trigger for a work up rather than the thyroid gland finding themselves.', metadata={'source': 'Papillary Thyroid Cancer in Children and Adolescents Does Not Differ in Growth Pattern and Metastatic Behavior.json___25', 'num': 25}),\n",
       " Document(page_content='With these findings, the authors indicate that children should not have less extensive neck operations than adolescents unless one is prepared to accept a high rate of regional recurrence in young', metadata={'source': 'Papillary Thyroid Cancer in Children and Adolescents Does Not Differ in Growth Pattern and Metastatic Behavior.json___26', 'num': 26}),\n",
       " Document(page_content='children.', metadata={'source': 'Papillary Thyroid Cancer in Children and Adolescents Does Not Differ in Growth Pattern and Metastatic Behavior.json___27', 'num': 27}),\n",
       " Document(page_content='It is quite clear that the management of thyroid cancer should be handled in tertiary centers that have excellent track records in both surgical management as well as other forms of treatment.', metadata={'source': 'Papillary Thyroid Cancer in Children and Adolescents Does Not Differ in Growth Pattern and Metastatic Behavior.json___28', 'num': 28}),\n",
       " Document(page_content='A feel of the thyroid should be part of every well-child visit. A recent report from Italy tells us how frequently, when a thyroid nodule is detected, various causes will be found.', metadata={'source': 'Papillary Thyroid Cancer in Children and Adolescents Does Not Differ in Growth Pattern and Metastatic Behavior.json___29', 'num': 29}),\n",
       " Document(page_content='1 The Italian investigators did a retrospective study on 120 patients with thyroid nodules diagnosed in childhood and adolescence accumulating data from 9 Italian centers.', metadata={'source': 'Papillary Thyroid Cancer in Children and Adolescents Does Not Differ in Growth Pattern and Metastatic Behavior.json___30', 'num': 30}),\n",
       " Document(page_content='Of children and adolescents presenting with thyroid nodules, 53% were shown to have a goitrous nodule (all were euthyroid).', metadata={'source': 'Papillary Thyroid Cancer in Children and Adolescents Does Not Differ in Growth Pattern and Metastatic Behavior.json___31', 'num': 31}),\n",
       " Document(page_content='Twenty-two percent of the youngsters had a papillary carcinoma (all were euthyroid). Some 13% had a follicular adenoma. Most of the latter children were hyperthyroid.', metadata={'source': 'Papillary Thyroid Cancer in Children and Adolescents Does Not Differ in Growth Pattern and Metastatic Behavior.json___32', 'num': 32}),\n",
       " Document(page_content='Five percent of youngsters had a follicular carcinoma, all of whom were euthyroid. Smaller percentages of youngsters with nodules had other forms of adenoma and carcinoma.', metadata={'source': 'Papillary Thyroid Cancer in Children and Adolescents Does Not Differ in Growth Pattern and Metastatic Behavior.json___33', 'num': 33}),\n",
       " Document(page_content='Background.dNeurosurgical resection is the standard treatment for subependymal giant-cell astrocytomas in patients with the tuberous sclerosis complex.', metadata={'source': 'Papillary Thyroid Cancer in Children and Adolescents Does Not Differ in Growth Pattern and Metastatic Behavior.json___34', 'num': 34}),\n",
       " Document(page_content='An alternative may be the use of everolimus, which inhibits the mammalian target of rapamycin, a protein regulated by gene products involved in the tuberous sclerosis complex.', metadata={'source': 'Papillary Thyroid Cancer in Children and Adolescents Does Not Differ in Growth Pattern and Metastatic Behavior.json___35', 'num': 35}),\n",
       " Document(page_content='Methods.dPatients 3 years of age or older with serial growth of subependymal giant-cell astrocytomas were eligible for this open-label study.', metadata={'source': 'Papillary Thyroid Cancer in Children and Adolescents Does Not Differ in Growth Pattern and Metastatic Behavior.json___36', 'num': 36}),\n",
       " Document(page_content='The primary efficacy end point was the change in volume of subependymal giant-cell astrocytomas between baseline and 6 months. We gave everolimus', metadata={'source': 'Papillary Thyroid Cancer in Children and Adolescents Does Not Differ in Growth Pattern and Metastatic Behavior.json___37', 'num': 37}),\n",
       " Document(page_content='The American Thyroid Association (ATA) classifies patients as low risk of recurrence if they have no local/distant metastases, all macroscopic tumour has been resected, no tumour invasion of loco-', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___1', 'num': 1}),\n",
       " Document(page_content='regional tissues/structures, the tumour does not have aggressive histology or vascular invasion, clinical N0 or ≤5 pathologic N1 micrometastases', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___2', 'num': 2}),\n",
       " Document(page_content='This article is protected by copyright.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___3', 'num': 3}),\n",
       " Document(page_content='All rights reserved (<0.2cm in largest dimension), or if 131 I is given with no 131 I uptake outside the thyroid bed on the first post-treatment whole body radioactive iodine (RAI) scan (1).', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___4', 'num': 4}),\n",
       " Document(page_content='In the first decade of follow-up, the initial risk of recurrence of ATA low-risk patients treated with total thyroidectomy and RAI remnant ablation is as low as 2-3%.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___5', 'num': 5}),\n",
       " Document(page_content='Following the response to initial therapy, the risk of recurrence in patients who demonstrate an excellent/indeterminate treatment response remains low at 0-2%.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___6', 'num': 6}),\n",
       " Document(page_content='The risk of recurrence, however, increases to 13% in patients with an incomplete treatment response (2).', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___7', 'num': 7}),\n",
       " Document(page_content='The ATA classifies patients as intermediate risk of recurrence if they have microscopic invasion of tumour into the perithyroidal tissue on initial histology, tumour with aggressive histology or', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___8', 'num': 8}),\n",
       " Document(page_content='vascular invasion, clinical N1 or >5 pathologic N1 with all involved lymph nodes <3cm in largest dimension or RAI-avid metastatic foci in the neck on the first posttreatment whole-body RAI scan (1).', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___9', 'num': 9}),\n",
       " Document(page_content='The initial risk of recurrent or persistent structural disease is as high as 21% in this group of patients.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___10', 'num': 10}),\n",
       " Document(page_content='However, the risk of recurrence declines to ≤2% in intermediate risk patients that demonstrate an excellent response to initial therapy (2).', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___11', 'num': 11}),\n",
       " Document(page_content='Previous studies have demonstrated that with current sensitive ultrasound scans (US) and thyroglobulin (Tg) assay, recurrences were detected mostly within 2-8 years after initial therapy (3,4,5).', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___12', 'num': 12}),\n",
       " Document(page_content=\"The ATA guidelines recommend that neck US should be performed at 6-12 months after surgery to establish patient's response to therapy, then periodically depending on risk of recurrence (1).\", metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___13', 'num': 13}),\n",
       " Document(page_content='This lack of clarity in recommendations on timing of follow-up US and fear of recurrence often lead to frequent surveillance tests, regardless of response to therapy.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___14', 'num': 14}),\n",
       " Document(page_content='Not all detectable findings require immediate diagnostic or therapeutic intervention and hence, it is important to differentiate actionable findings from non-actionable findings.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___15', 'num': 15}),\n",
       " Document(page_content='The aim of this study was to evaluate the clinical utility of routine neck US in ATA low-intermediate risk papillary thyroid carcinoma (PTC) patients with no structural disease on neck US and non-', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___16', 'num': 16}),\n",
       " Document(page_content='stimulated thyroglobulin <1.0ng/mL after initial therapy.\\nThe hypotheses was that frequent US screening is more likely to identify non-actionable findings than clinically significant disease.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___17', 'num': 17}),\n",
       " Document(page_content='The study was approved by the hospital ethics committee.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___18', 'num': 18}),\n",
       " Document(page_content='We retrospectively analysed the medical records of 1086 patients with thyroid cancer treated with total thyroidectomy, with/without RAI ablation, who had serial neck US performed during their follow-', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___19', 'num': 19}),\n",
       " Document(page_content='up at our centres between 1998-2017.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___20', 'num': 20}),\n",
       " Document(page_content='This article is protected by copyright. All rights reserved', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___21', 'num': 21}),\n",
       " Document(page_content='The inclusion criteria of the study was patients had to have low/intermediate risk PTC (in accordance to the 2015 ATA guidelines)(1), treated with total thyroidectomy with/without RAI ablation, a non-', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___22', 'num': 22}),\n",
       " Document(page_content='stimulated Tg <1.0ng/mL in the absence of interfering anti-Tg antibodies and no suspicious findings on post-operative neck US.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___23', 'num': 23}),\n",
       " Document(page_content='A total of 93 patients (49 with ATA low risk of recurrence, 44 with ATA intermediate risk of recurrence) fulfilled the inclusion criteria for analysis.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___24', 'num': 24}),\n",
       " Document(page_content='The remaining patients were excluded based on the following findings: other histological subtypes of thyroid cancer, ATA high risk of recurrence, non-stimulated Tg >1.0ng/mL, interfering anti-Tg', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___25', 'num': 25}),\n",
       " Document(page_content='antibodies, persistent suspicious findings on post-operative neck US, only 0-1 neck US during follow-up and lobectomy as the only surgery(Figure 1).', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___26', 'num': 26}),\n",
       " Document(page_content='The 93 patients included were staged post-operatively using the American Joint Committee Cancer (AJCC) 7 th edition staging system(6) as there was insufficient information to classify patients based', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___27', 'num': 27}),\n",
       " Document(page_content='on the newer AJCC 8 th edition staging system. These patients were diagnosed prior to the adoption of the AJCC 8 th edition staging system.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___28', 'num': 28}),\n",
       " Document(page_content='US were ordered as part of routine US surveillance or if there was abnormal clinical findings or rising Tg levels.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___29', 'num': 29}),\n",
       " Document(page_content='US was performed according to standard protocol that included gray scale and colour Doppler US of the thyroid bed and cervical lymph nodes in all neck compartments by technologists, supervised by', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___30', 'num': 30}),\n",
       " Document(page_content='experienced radiologists. The technologists and respective institutional radiologists reviewed the images and reports were uploaded on our picture archiving system.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___31', 'num': 31}),\n",
       " Document(page_content='US images were reviewed by the study team if there were sonographically indeterminate/suspicious findings reported by the radiologists.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___32', 'num': 32}),\n",
       " Document(page_content='US reports include size, shape, echogenicity, internal vascularity, presence of cystic changes and calcifications of thyroid bed nodules and cervical lymph nodes.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___33', 'num': 33}),\n",
       " Document(page_content='Size was reported in 3 dimensions and echogenicity was characterized relative to strap muscles.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___34', 'num': 34}),\n",
       " Document(page_content='Microcalcifications were defined as punctate bright spots with no acoustic shadowing and vascularity was defined as the presence of Doppler flow.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___35', 'num': 35}),\n",
       " Document(page_content='If there was a change from prior US studies, a comment was made in the report. US findings were classified as suspicious, indeterminate or normal.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___36', 'num': 36}),\n",
       " Document(page_content='We defined sonographically suspicious findings as thyroid bed nodules with ≥1 of the following features; microcalcifications, increased vascularity or structurally progressive lesions regardless of', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___37', 'num': 37}),\n",
       " Document(page_content='size and the presence of cervical lymph node with ≥1 of the following features; microcalcifications, cystic areas or peripheral/diffuse vascularity.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___38', 'num': 38}),\n",
       " Document(page_content='Indeterminate findings were defined as rounded, avascular cervical lymph nodes with absent fatty hilum or avascular thyroid bed nodules.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___39', 'num': 39}),\n",
       " Document(page_content='We defined sonographically normal findings as ≥2 consecutive negative post-operative neck US.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___40', 'num': 40}),\n",
       " Document(page_content='This article is protected by copyright.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___41', 'num': 41}),\n",
       " Document(page_content='All rights reserved The use of cross-sectional imaging (computed tomography scan or magnetic resonance imaging) as well as functional imaging (RAI whole-body scan or 18-fluorodeoxyglucose-positron', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___42', 'num': 42}),\n",
       " Document(page_content='emission tomography scan) were obtained at the discretion of the clinician and reviewed.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___43', 'num': 43}),\n",
       " Document(page_content='If iodine uptake was observed in the thyroid bed and lateral neck region, these lesions were presumed to show RAI avidity.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___44', 'num': 44}),\n",
       " Document(page_content='All Tg values in Singapore were measured using radioimmunoassay, e411 (Roche) or E170 (Roche) with a functional sensitivity of 0.5ng/mL before 2015.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___45', 'num': 45}),\n",
       " Document(page_content='Subsequently, the Tg assay was changed in 2015 to Kryptor (Brahms) and e411 (Roche) with a functional sensitivity of 0.1ng/mL.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___46', 'num': 46}),\n",
       " Document(page_content='Tg values in Saudi Arabia were measured using e801 (Cobas) with a functional sensitivity of 0.1ng/mL whereas Tg values in Argentina were measured using QL immulite and had a functional sensitivity of', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___47', 'num': 47}),\n",
       " Document(page_content='0.6ng/mL. Anti-Tg antibodies were measured using either radioimmunoassay, QL immulite, Immulite 2000 (Siemens), Kryptor (Brahms), e411 (Roche) or e801 (Cobas).', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___48', 'num': 48}),\n",
       " Document(page_content='Patients were followed up at 6-12 month intervals at the discretion of the attending physician based on the clinical course and risk of recurrence of the patient.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___49', 'num': 49}),\n",
       " Document(page_content='Surveillance testing included serum Tg measurement on thyroid stimulating hormone (TSH) suppressive therapy and neck US.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___50', 'num': 50}),\n",
       " Document(page_content='A diagnostic whole-body scan and a stimulated Tg value were ordered when deemed appropriate by the physician.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___51', 'num': 51}),\n",
       " Document(page_content='The study period was defined as the time from study entry to the last available medical records up to February 2017.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___52', 'num': 52}),\n",
       " Document(page_content='The clinical endpoint included structural neck recurrence, defined as a newly identified locoregional metastases with/without abnormal Tg.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___53', 'num': 53}),\n",
       " Document(page_content='Structural neck recurrence is based on histology and sonographically suspicious findings.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___54', 'num': 54}),\n",
       " Document(page_content='Response to therapy was classified as excellent, indeterminate, biochemical incomplete or structural incomplete based on the ATA 2015 thyroid cancer management guidelines.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___55', 'num': 55}),\n",
       " Document(page_content='Patients were considered to have an excellent treatment response if they had non-stimulated Tg <0.2ng/mL or stimulated serum Tg <1.0ng/mL after RAI ablation, with no detectable TgAb and non-structural', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___56', 'num': 56}),\n",
       " Document(page_content='evidence of disease on neck US and/or cross sectional or nuclear medicine imaging.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___57', 'num': 57}),\n",
       " Document(page_content='Patients were considered to have an indeterminate response if they had a non-stimulated serum Tg between 0.2-1.0ng/mL, stimulated serum Tg ≥1-10ng/mL after RAI ablation, stable or declining TgAb or', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___58', 'num': 58}),\n",
       " Document(page_content='non-specific changes on neck US and / or cross sectional or nuclear medicine imaging.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___59', 'num': 59}),\n",
       " Document(page_content='Patients were considered to have biochemical incomplete treatment response if they had a non-stimulated Tg >1ng/mL after RAI ablation, simulated serum Tg >10ng/mL or rising Tg/TgAb values without', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___60', 'num': 60}),\n",
       " Document(page_content='structural evidence of disease on imaging. Patients with structural evidence of disease on imaging regardless of Tg/TgAb levels were considered to have structural incomplete response.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___61', 'num': 61}),\n",
       " Document(page_content='This article is protected by copyright.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___62', 'num': 62}),\n",
       " Document(page_content='All rights reserved Indeterminate US abnormalities identified during follow-up evaluations that were stable, did not require immediate diagnostic or therapeutic intervention, and not considered to be', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___63', 'num': 63}),\n",
       " Document(page_content='structural disease recurrence (based on cytology, histology or RAI imaging) were defined as non-actionable findings.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___64', 'num': 64}),\n",
       " Document(page_content='Continuous data was presented as mean and standard deviation (SD) or median and ranges, as appropriate for each variable. The χ2 test was performed to assess for differences between 2 proportions.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___65', 'num': 65}),\n",
       " Document(page_content='Analysis was performed using SPSS software (Version 18.0.1; SPSS, Inc, Chicago, IL). A P value of ≤.05 was considered statistically significant.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___66', 'num': 66}),\n",
       " Document(page_content='The majority of PTC patients were female (86%, 80/93) and the median age at diagnosis was 49 years (range 16-82 years)(Table 1). The median follow up duration was 5 years (range 1.8-17.0 years).', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___67', 'num': 67}),\n",
       " Document(page_content='Overall, 68% had AJCC Stage I, 5% had AJCC Stage II, 20% had AJCC Stage III and 7% had AJCC Stage IV disease.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___68', 'num': 68}),\n",
       " Document(page_content='As patients with distant metastases were excluded from the study, all patients in the study who had Stage IV disease were N1b and none had distant metastases or T4 disease.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___69', 'num': 69}),\n",
       " Document(page_content='Initial therapy included total thyroidectomy without neck dissection in 67%, central neck dissection in 26% and central and lateral neck dissection in 8% of patients. 86% of patients received RAI', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___70', 'num': 70}),\n",
       " Document(page_content='after total thyroidectomy with a median cumulative RAI activity of 100mCi.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___71', 'num': 71}),\n",
       " Document(page_content='In the ATA low risk of recurrence group, 37/49 patients had excellent response to treatment, 3/49 had biochemical incomplete response to treatment and 9/49 had indeterminate response to treatment.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___72', 'num': 72}),\n",
       " Document(page_content='Two out of 49 patients (4.1%) in the ATA low risk of recurrence group, which had initial excellent response to treatment, were identified to have a recurrence of disease confirmed on biopsy(Figure 2).', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___73', 'num': 73}),\n",
       " Document(page_content='In the ATA intermediate risk of recurrence group, 21/44 had excellent response to treatment, 4/44 had biochemical incomplete response to treatment and 19/44 had indeterminate response to treatment.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___74', 'num': 74}),\n",
       " Document(page_content='Three out of 44 patients (6.8%) in the ATA intermediate risk of recurrence group had recurrence of disease confirmed on biopsy and RAI whole-body scan.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___75', 'num': 75}),\n",
       " Document(page_content='Two of the patients with a recurrence had initial excellent response to treatment and one had indeterminate response to treatment(Figure 2).', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___76', 'num': 76}),\n",
       " Document(page_content='This article is protected by copyright.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___77', 'num': 77}),\n",
       " Document(page_content='All rights reserved Five out of 93 (5.4%) developed suspicious US findings during surveillance and this was identified at a median of 2.5 years after surgery (range 1.8-3.7 years)(Table 2).', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___78', 'num': 78}),\n",
       " Document(page_content='These 5 patients underwent a median of 7 neck US (range 4-15 US) over a median follow-up of 7.3 years (range 3.3-13 years)(Figure 3). All these patients had total thyroidectomy with RAI ablation.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___79', 'num': 79}),\n",
       " Document(page_content='One patient (20%) underwent central neck dissection. Two out of 5 patients (40%) with suspicious US findings had underlying lymphocytic thyroiditis.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___80', 'num': 80}),\n",
       " Document(page_content='Two out of 5 patients with structural disease had rising Tg levels and one out of 5 patients had a Tg level which went from 0.1 to 0.2ng/mL(Table 2).', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___81', 'num': 81}),\n",
       " Document(page_content='The rise in Tg level from 0.1 to 0.2ng/mL in this patient is likely due to assay variation rather than a true rise in Tg.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___82', 'num': 82}),\n",
       " Document(page_content='All the patients with suspicious US findings had small volume disease on neck ultrasound, with central neck nodules/ nodes<8mm and lateral neck nodes<10mm in the smallest dimension, not meeting ATA', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___83', 'num': 83}),\n",
       " Document(page_content='guideline size criteria for further intervention(12)(Table 2).', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___84', 'num': 84}),\n",
       " Document(page_content='Nineteen out of 93 cases (20.4%) developed indeterminate features on neck US(Figure 4).', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___85', 'num': 85}),\n",
       " Document(page_content='These patients underwent a median of 5 neck US (range 2-8 US) over a median follow-up of 4 years (range 1.8-10.2 years).', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___86', 'num': 86}),\n",
       " Document(page_content='All these patients had total thyroidectomy and 4 patients (21%) had central neck dissection. Sixteen out of 19 patients (84.2%) had RAI.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___87', 'num': 87}),\n",
       " Document(page_content='The patients with indeterminate US findings went on to have 3 biopsies under US guidance with benign cytological results suggesting initial false positive US abnormalities, 6 RAI diagnostic whole-body', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___88', 'num': 88}),\n",
       " Document(page_content='scans, 1 patient had empiric radioiodine therapy (75 mCi), 1 computed tomography scan and 19 additional neck US in total over a median followup of 2.3 years (range 1.4-6 years(Figure 3).', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___89', 'num': 89}),\n",
       " Document(page_content='None of these investigations revealed structural disease, indicating that the indeterminate US findings were non-actionable.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___90', 'num': 90}),\n",
       " Document(page_content='Two out of 19 patients (10.5%) with indeterminate US findings had underlying lymphocytic thyroiditis.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___91', 'num': 91}),\n",
       " Document(page_content='Of the 93 patients, 69 (74.2%) patients continued to have normal post-operative neck US over a median follow-up of 5.8 years (range 2-17 years).', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___92', 'num': 92}),\n",
       " Document(page_content='These patients had a median of 3 neck US (range 2-9 US) during the follow-up(Figure 3). None of these patients had diagnostic RAI whole body scans.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___93', 'num': 93}),\n",
       " Document(page_content='All the patients had total thyroidectomy and 26 patients (37.5%) had either central (n=20) or lateral neck dissection (n=6). Fifty-nine out of 69 patients (85.5%) had RAI.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___94', 'num': 94}),\n",
       " Document(page_content='Seventeen out of 69 patients (24.6%) with a normal post-operative neck US had underlying lymphocytic thyroiditis.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___95', 'num': 95}),\n",
       " Document(page_content='The finding of suspicious, indeterminate or normal post-operative neck US was not significantly associated with underlying lymphocytic thyroiditis status (p=0.27) or whether neck dissection was', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___96', 'num': 96}),\n",
       " Document(page_content='performed (p=0.32). The extent of neck dissection did not affect grouping of patients into ATA low and intermediate risk (p=0.09).', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___97', 'num': 97}),\n",
       " Document(page_content='We reviewed the medical records of 93 patients with ATA low-intermediate risk thyroid cancer treated with total thyroidectomy with/without RAI ablation and had a non-stimulated serum Tg <1ng/mL in the', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___98', 'num': 98}),\n",
       " Document(page_content='absence of interfering TgAb without suspicious US findings on their initial post-operative neck US.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___99', 'num': 99}),\n",
       " Document(page_content='We found that US detected low-volume, non-actionable structural neck recurrence in 5.4% of the cohort, but also detected indeterminate US abnormalities in 20.4% of patients, leading to additional', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___100', 'num': 100}),\n",
       " Document(page_content='tests, which did not detect significant disease. This indicated that the indeterminate US findings were also non-actionable as well.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___101', 'num': 101}),\n",
       " Document(page_content='Patients with ATA low-intermediate risk thyroid cancer had an overall rate of recurrence of 5.4% (4% in the ATA low risk group and 6.8% in the ATA intermediate risk group).', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___102', 'num': 102}),\n",
       " Document(page_content='This was identified during routine US screening at a median of 2.5 years (range 1.8-3.7 years) after surgery. These patients had small volume disease on neck ultrasound.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___103', 'num': 103}),\n",
       " Document(page_content='A study done by Rondeau et al in 2011 showed that over a median clinical follow-up of 5 years, 9% of patients had increase in size of at least one thyroid bed nodule but the rate of growth was only', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___104', 'num': 104}),\n",
       " Document(page_content='1.3mm/year (7). Another study by Robenshtok et al in 2012 showed that suspicious cervical lymph nodes (median lymph node size 1.3cm) usually remain stable with the rate of growth of 1.5mm/year.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___105', 'num': 105}),\n",
       " Document(page_content='After a median follow-up of 3.5 years, 20% (33 of 166) of patients demonstrated an increase in the size of suspicious lymph node of ≥3mm and only 9% (15 of 166) had an increase ≥5mm.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___106', 'num': 106}),\n",
       " Document(page_content='In 14% of patients (23 of 166), no suspicious lymph node was detected at the end of follow-up (8).', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___107', 'num': 107}),\n",
       " Document(page_content='These studies suggest that often, small volume disease is stable and may not need further intervention.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___108', 'num': 108}),\n",
       " Document(page_content='This is in keeping with the ATA 2015 recommendations 65 and 71 that only patients with central neck nodes ≥8mm and lateral neck nodes ≥10mm in the smallest dimension are candidates for treatment and', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___109', 'num': 109}),\n",
       " Document(page_content='neck nodes smaller than these criteria, although detected may not need further intervention (12).', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___110', 'num': 110}),\n",
       " Document(page_content='Earlier studies have shown that recurrence from thyroid cancer may be observed many years after the initial treatment.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___111', 'num': 111}),\n",
       " Document(page_content='In a study of 1355 patients in the United States with papillary and follicular thyroid cancer by Mazzaferri et al, 57% of recurrences were diagnosed in the first 5 years of follow-up whereas 43% of', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___112', 'num': 112}),\n",
       " Document(page_content='the recurrences were detected 5-35 years after initial treatment (9).', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___113', 'num': 113}),\n",
       " Document(page_content='In another study from the United States by Hay et al evaluating 2444 patients with PTC (60% with TNM Stage I disease), recurrences of thyroid cancer were detected up to 60 years (10).', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___114', 'num': 114}),\n",
       " Document(page_content='These older studies were done when post-operative neck US may not have been the standard of care and when sensitive serum Tg and high-resolution neck US were not readily available.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___115', 'num': 115}),\n",
       " Document(page_content='In a study by Durante et al in 2010, 312 micropapillary thyroid cancer Italian patients treated with total thyroidectomy with/without RAI remnant ablation over a median follow-up of 6.7 years (range 5', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___116', 'num': 116}),\n",
       " Document(page_content='-23 years) were observed. All of these patients had a negative initial and final post-operative neck US and none of these patients had recurrent disease during surveillance(11)(Figure 5).', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___117', 'num': 117}),\n",
       " Document(page_content='The recurrence rate of 1.2% at a median of 2.8 years (range 1.6-4.1 years) was observed in the ATA low risk thyroid cancer group(4) while the recurrence rate was 10% at a median of 6.3 years (range', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___118', 'num': 118}),\n",
       " Document(page_content='3.0-14.5 years) after the last surgery in the ATA intermediate risk thyroid cancer group(5)(Figure 5).', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___119', 'num': 119}),\n",
       " Document(page_content='This article is protected by copyright. All rights reserved In 2018, Verburg et al studied 773 low (n=391) and high risk (n=381) German patients with papillary and follicular thyroid cancer.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___120', 'num': 120}),\n",
       " Document(page_content='This study showed no recurrences from 2008-2012 in patients with Tg<1mcg/L (using sensitive Tg assays)(13,14)(Figure 5).', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___121', 'num': 121}),\n",
       " Document(page_content='In a recent study by Grani et al in 2019, 226 patients with PTC with sonographically normal neck lymph nodes and unstimulated serum Tg levels that were undetectable (<0.20ng/mL) or low (0.21-0.99 ng/', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___122', 'num': 122}),\n",
       " Document(page_content='mL) at 1 year evaluation were followed up over a median of 6 -7 years.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___123', 'num': 123}),\n",
       " Document(page_content='In patients with an undetectable Tg level (<0.20 ng/mL) at the 1 year evaluation, sonographically suspicious neck lymph nodes were found in 1.2% of patients at 3 years and in 1.8% at the last visit [', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___124', 'num': 124}),\n",
       " Document(page_content='negative predictive values (NPVs) of 1 year Tg <0.20 ng/mL : 98.8% (95% CI 95.8%-99.9%) and 98.2% (95%-99.6%), respectively].', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___125', 'num': 125}),\n",
       " Document(page_content='Similar NPVs were observed for low detectable 1 year Tg levels [98.2% (90.3%-99.9%) and 94.5% (84.9%-98.9%) at the 3 year and last visits, respectively]. 75% of the nodal lesions (6 out of 8 patients)', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___126', 'num': 126}),\n",
       " Document(page_content='were likely false positive and all 8 patients did not require further intervention.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___127', 'num': 127}),\n",
       " Document(page_content='One of the sonographically suspicious nodal lesions developed unstimulated Tg ≥ 1ng/mL, whereas the other had undetectable Tg <0.2ng/ml.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___128', 'num': 128}),\n",
       " Document(page_content='This study concluded that low-intermediate risk PTC patients with negative US findings and unstimulated Tg <1ng/mL at the 1 year evaluation can be safely followed with clinical assessments and', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___129', 'num': 129}),\n",
       " Document(page_content='unstimulated serum Tg levels. Neck US might be repeated if unstimulated Tg >1ng/mL(15).', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___130', 'num': 130}),\n",
       " Document(page_content='The results from our study show that recurrence of thyroid cancer in ATA low-intermediate risk patients was identified at a median of 2.5 years (range 1.8-3.7 years) after surgery, similar to some of', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___131', 'num': 131}),\n",
       " Document(page_content='the recent studies(3,4)(Figure 5). The structural recurrences in the study by Grani et al in 2019 (15) and our study were small-volume diseases that were not actionable.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___132', 'num': 132}),\n",
       " Document(page_content='However, the long term trajectory of these findings remain to be characterized in future longer term studies.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___133', 'num': 133}),\n",
       " Document(page_content='Conversely, routine surveillance neck US identified 20.4% indeterminate findings in our study, which led to further interventions and did not identify clinically significant disease.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___134', 'num': 134}),\n",
       " Document(page_content='We recognize that some of the indeterminate US findings could potentially develop into structural disease recurrence during long-term follow-up but none of the indeterminate findings in our study were', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___135', 'num': 135}),\n",
       " Document(page_content='observed to have clinically significant structural disease recurrence during the median follow-up of 4 years (range 1.8-10.2 years).', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___136', 'num': 136}),\n",
       " Document(page_content='In recent years, there has been an increasing number of thyroid cancer patients in remission who have indeterminate neck US findings, which subsequently turn out to be false positive findings.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___137', 'num': 137}),\n",
       " Document(page_content='In the two studies by Yang et al (4,5), 67% of ATA low risk patients and 57% of ATA intermediate risk patients had false positive ultrasound results.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___138', 'num': 138}),\n",
       " Document(page_content='Similar results were observed in another study by Verburg et al (13), where 43.9% of differentiated thyroid cancer patients had false positive results on neck US.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___139', 'num': 139}),\n",
       " Document(page_content='The study by Verburg et al concluded that after total thyroidectomy and 131 I ablation, neck US should be reserved for patients with a Tg of ≥1mcg/L in anti-Tg antibody negative patients, regardless', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___140', 'num': 140}),\n",
       " Document(page_content='of initial risk. This is because patients with Tg <1mcg/L have an extremely low rate of true positive neck US, but a considerable rate of false positive findings.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___141', 'num': 141}),\n",
       " Document(page_content='This article is protected by copyright.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___142', 'num': 142}),\n",
       " Document(page_content='All rights reserved It is important to note that our findings are based on retrospective analysis and ideally, this should be confirmed in a randomized prospective study.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___143', 'num': 143}),\n",
       " Document(page_content='Other limitations of our study include selection bias, small patient number, variable Tg assays used in different centres with one centre having a Tg functional sensitivity of 0.6mcg/L which is higher', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___144', 'num': 144}),\n",
       " Document(page_content='than the ATA 2015 cut off of <0.2mcg/L for excellent treatment response.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___145', 'num': 145}),\n",
       " Document(page_content='The data for the time point for the initial postoperative ultrasound evaluation was not available and we acknowledge this as one of the limitations of the study.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___146', 'num': 146}),\n",
       " Document(page_content='The strengths of our study are that despite different standard of care and variable Tg assays in different centres, results are similar to other observational studies (4,5,13) hence this can be', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___147', 'num': 147}),\n",
       " Document(page_content='applied to thyroid cancer patients in other countries.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___148', 'num': 148}),\n",
       " Document(page_content='In conclusion, the overall structural recurrence rate observed in our study of ATA low-intermediate risk patients was 5.4% over a median follow-up period of 2.5 years (range 1.8-3.7 years) after', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___149', 'num': 149}),\n",
       " Document(page_content='surgery. Importantly, the recurrent disease was identified as small volume metastatic cervical lymph nodes that were often non-actionable.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___150', 'num': 150}),\n",
       " Document(page_content='Conversely, continued use of routine US identified non-actionable findings in 20.4% of patients leading to unnecessary investigations and interventions.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___151', 'num': 151}),\n",
       " Document(page_content='Thus, continued long term follow-up with aggressive US in low-intermediate risk patients with an excellent response to therapy has the potential to cause more harm than good.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___152', 'num': 152}),\n",
       " Document(page_content='Therefore, the frequency and timing of routine neck surveillance should be tailored according to risk of recurrence and response to treatment.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___153', 'num': 153}),\n",
       " Document(page_content='After 5 years of follow-up, we no longer recommend routine use of screening ultrasonography in lowintermediate risk patients demonstrating an excellent response to therapy.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___154', 'num': 154}),\n",
       " Document(page_content='This research did not receive any specific grant from any funding agency in the public, commercial of not-forprofit sector', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___155', 'num': 155}),\n",
       " Document(page_content='The data that support the findings of the study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical considerations.', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___156', 'num': 156}),\n",
       " Document(page_content='This article is protected by copyright. All rights reserved', metadata={'source': 'Frequent neck US in papillary thyroid cancer likely detects non_actionable findings.json___157', 'num': 157}),\n",
       " Document(page_content='Papillary thyroid cancer (PTC) is the most common histologic type of thyroid cancer which accounts for 85 -90% of thyroid malignancies and its incidence has been increasing over the years.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___1', 'num': 1}),\n",
       " Document(page_content='1 PTCs rarely behave as aggressive tumors clinically, with a 10-year survival rate of approximately 95%.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___2', 'num': 2}),\n",
       " Document(page_content='2 However, a small proportion of cases with aggressive features at presentation develop early distant metastasis or relapse and are associated with adverse outcomes.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___3', 'num': 3}),\n",
       " Document(page_content='In recent decades, there has been significant progress in understanding the molecular profiles and the pathogenesis of thyroid cancer, especially papillary thyroid carcinoma (PTC).', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___4', 'num': 4}),\n",
       " Document(page_content='Several molecular markers have been shown to have promising prognostic value in PTC patients including BRAF mutation and TERT promoter mutations.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___5', 'num': 5}),\n",
       " Document(page_content='[3][4][5][6] However, there are still continuing debates', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___6', 'num': 6}),\n",
       " Document(page_content='This article is protected by copyright. All rights reserved.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___7', 'num': 7}),\n",
       " Document(page_content=\"regarding which molecular markers should be used or how to combine them to better assess patients' prognosis.\", metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___8', 'num': 8}),\n",
       " Document(page_content='[7][8][9] In this meta-analysis, we aimed to investigate the clinicopathological implication of concurrent BRAF and TERT promoter mutations on PTC patients.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___9', 'num': 9}),\n",
       " Document(page_content='We searched for relevant articles in four electronic databases, including PubMed, Web of Science, Scopus and VHL from inception to September 2016.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___10', 'num': 10}),\n",
       " Document(page_content='The following search term was used: BRAF AND TERT AND (papillary thyroid) AND (carcinoma OR cancer).', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___11', 'num': 11}),\n",
       " Document(page_content='We also searched for potential studies by reviewing the citations within the included studies and reviews.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___12', 'num': 12}),\n",
       " Document(page_content='Our study protocol strictly followed the recommendation of Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement. 10', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___13', 'num': 13}),\n",
       " Document(page_content='All search results from each electronic database were imported into Endnote (Thompson Reuters, PA, US) and duplicates were deleted.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___14', 'num': 14}),\n",
       " Document(page_content='Titles and abstracts of included studies were independently screened by two reviewers.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___15', 'num': 15}),\n",
       " Document(page_content='Studies were included if they reported the clinicopathological features of different genotypes when combining BRAF and TERT promoter mutations.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___16', 'num': 16}),\n",
       " Document(page_content='We excluded studies if they were (i) studies on other thyroid cancer subtypes other than PTC (ii) case reports, (iii) reviews, (iv) posters, conference papers, theses or books, and (v) duplicated', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___17', 'num': 17}),\n",
       " Document(page_content='articles. Discordant results between two reviewers were resolved by discussion and consensus.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___18', 'num': 18}),\n",
       " Document(page_content='Full-text of all potential studies were screened independently by two reviewers. Available data were extracted into a predefined extraction form.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___19', 'num': 19}),\n",
       " Document(page_content='The following data were extracted from fulltext papers: authors, institution, city, country, publication year, surgical period, study design, number of patients, mutational detection method, follow-up', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___20', 'num': 20}),\n",
       " Document(page_content='period and clinicopathological data (tumor size, multifocality, extrathyroidal extension, nodal metastasis, distant metastasis, AJCC stage and tumor', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___21', 'num': 21}),\n",
       " Document(page_content='This article is protected by copyright. All rights reserved. recurrence) of each genotype. Any disagreements between two reviewers, if present, were resolved again by discussion and consensus.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___22', 'num': 22}),\n",
       " Document(page_content='We used the Newcastle -Ottawa Scale (NOS) to evaluate the quality of included studies in our meta-analyses.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___23', 'num': 23}),\n",
       " Document(page_content='11 Two reviewers independently awarded stars for cohort or case-control studies (maximum nine stars) based on a developed checklist.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___24', 'num': 24}),\n",
       " Document(page_content='11 Studies awarded at least six stars were considered moderate to high-quality studies and those with a NOS value of less than six were regarded low-quality studies.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___25', 'num': 25}),\n",
       " Document(page_content='We used Review Manager 5.3 (Cochrane Collaborative, Oxford, UK) for statistical analysis.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___26', 'num': 26}),\n",
       " Document(page_content='Pooled estimates of ORs and corresponding 95% CIs were calculated using random-effect model.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___27', 'num': 27}),\n",
       " Document(page_content='We compared the clinicopathological features among the four genotype groups: PTCs with concurrent BRAF and TERT promoter mutations (BRAF+/TERT+), with BRAF mutation alone (BRAF+ only), with TERT', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___28', 'num': 28}),\n",
       " Document(page_content='promoter mutation alone (TERT+ only) and without both mutations (BRAF-/TERT-).', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___29', 'num': 29}),\n",
       " Document(page_content='Among-study heterogeneity was assessed by the I 2 statistic.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___30', 'num': 30}),\n",
       " Document(page_content=\"12 Egger's regression test and funnel plot were carried out to further assess the presence of publication bias and calculated by Meta-Essentials: Workbook for meta-analysis.\", metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___31', 'num': 31}),\n",
       " Document(page_content='13 A p value less than 0.05 was considered statistically significant publication bias.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___32', 'num': 32}),\n",
       " Document(page_content='After searching four electronic databases and deleting duplicates, we found 111 articles for abstract screening step.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___33', 'num': 33}),\n",
       " Document(page_content='Following title and abstract screening, 22 potential studies were selected for full-text reading. We further excluded 11 studies that did not meet the inclusion criteria after this step.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___34', 'num': 34}),\n",
       " Document(page_content='Finally, 11 studies with 3911 PTC patients were included for final analysis (Figure 1). 4,[7][8][9][14][15][16][17][18][19][20]', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___35', 'num': 35}),\n",
       " Document(page_content='This article is protected by copyright. All rights reserved.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___36', 'num': 36}),\n",
       " Document(page_content='The characteristics of included studies are described in Table 1.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___37', 'num': 37}),\n",
       " Document(page_content='The impact of BRAF or TERT promoter mutation alone or their coexistence on clinicopathological features of PTC were reported in 11 studies.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___38', 'num': 38}),\n",
       " Document(page_content='Overall, the group of PTCs with BRAF+ only was the most common molecular group (53.5%), followed by PTCs with BRAF-/TERT-(38.8%), BRAF+/TERT+ (5.8%), while the group of PTCs with only TERT+ (1.9%) was', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___39', 'num': 39}),\n",
       " Document(page_content='least common.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___40', 'num': 40}),\n",
       " Document(page_content='Our results showed that PTCs harboring BRAF+/TERT+ were significantly associated with more aggressive clinical courses as compared with tumors with BRAF+ only (Table 2).', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___41', 'num': 41}),\n",
       " Document(page_content='In addition, PTCs with BRAF+/TERT+ also showed its increased aggressiveness in several clinical features (pT3/T4, extrathyroidal extension, advanced AJCC stage and tumor recurrence) when compared with', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___42', 'num': 42}),\n",
       " Document(page_content='PTCs harboring TERT promoter mutation only (Table 2).', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___43', 'num': 43}),\n",
       " Document(page_content='When we compared PTCs with either BRAF and TERT promoter mutation alone, there were no significant differences in the clinicopathological features between these two groups, except PTCs with TERT', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___44', 'num': 44}),\n",
       " Document(page_content='mutation only are more likely to metastasize to distant organs than PTCs harboring only BRAF mutation (Table 2).', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___45', 'num': 45}),\n",
       " Document(page_content='Heterogeneity existed in several analyses, particularly in the comparison of BRAF+/TERT+ vs BRAF+ only.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___46', 'num': 46}),\n",
       " Document(page_content='PTCs with TERT+ only showed enhanced aggressiveness in comparison with PTCs with BRAF-/TERTin some clinicopathological features including nodal metastases, distant metastasis and tumor recurrence (', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___47', 'num': 47}),\n",
       " Document(page_content='Table 3).', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___48', 'num': 48}),\n",
       " Document(page_content='We also found that PTCs with BRAF+ only were associated with increased risk for aggressive tumor behaviors when compared with PTCs with BRAF-/TERTsuch as higher risk for pT3/T4, extrathyroidal', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___49', 'num': 49}),\n",
       " Document(page_content='extension, nodal metastasis and advanced AJCC stage (Table 3).', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___50', 'num': 50}),\n",
       " Document(page_content='This article is protected by copyright. All rights reserved.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___51', 'num': 51}),\n",
       " Document(page_content='We used sensitivity analysis by removing each of the included studies to find which studies influenced the degree of heterogeneity.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___52', 'num': 52}),\n",
       " Document(page_content='All significant pooled results following the leave-one-out method remained unaffected.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___53', 'num': 53}),\n",
       " Document(page_content='We could not perform meta-regression to further explore the origin of heterogeneity because of small numbers of included studies.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___54', 'num': 54}),\n",
       " Document(page_content='The NOS tool was used to assess the quality of included studies. All of included studies were retrospective studies and the number of stars awarded to each study ranged from five to six stars.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___55', 'num': 55}),\n",
       " Document(page_content='Details of given stars within each domain of NOS are described in Table 4.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___56', 'num': 56}),\n",
       " Document(page_content='Funnel plot observation did not show strong evidence of publication bias among the set of studies.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___57', 'num': 57}),\n",
       " Document(page_content=\"In addition, Egger's regression test of all effects did not suggest any evidence of publication bias (data not shown).\", metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___58', 'num': 58}),\n",
       " Document(page_content='shown several clinical factors have been shown to have prognostic value such as old age, large tumor size, the presence of nodal and distant metastasis or extrathyroidal extension.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___59', 'num': 59}),\n",
       " Document(page_content='21 The understanding of pathogenesis and molecular profiles in thyroid cancer has been much improved in recent years with the rapid growth of translational medicine.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___60', 'num': 60}),\n",
       " Document(page_content='Therefore, investigating the usefulness of genetic events as trustworthy prognostic markers for risk stratification and patient management is essential.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___61', 'num': 61}),\n",
       " Document(page_content='Since 2003, the significant role of BRAF mutations, especially BRAF V600E, in tumor aggressiveness have been extensively studied.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___62', 'num': 62}),\n",
       " Document(page_content='In several published meta-analyses, the BRAF V600E has been summarized to correlate with aggressive clinical course in PTC patients, such as increased rate of extrathyroidal extension and nodal', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___63', 'num': 63}),\n",
       " Document(page_content='metastasis.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___64', 'num': 64}),\n",
       " Document(page_content='22,23 TERT promoter mutation, the more recently discovered mutation in thyroid cancer, has been found to associate with aggressive clinicopathological features and poor outcomes in PTCs, especially', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___65', 'num': 65}),\n",
       " Document(page_content='its association with increased risk for distant metastasis. 7,8,24 Xing and colleagues first demonstrated that coexisting BRAF V600E and TERT', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___66', 'num': 66}),\n",
       " Document(page_content='This article is protected by copyright. All rights reserved.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___67', 'num': 67}),\n",
       " Document(page_content='promoter mutations defines a group of PTCs with even worse clinicopathological outcomes. 7 However, conflicting results were reported in other studies.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___68', 'num': 68}),\n",
       " Document(page_content='14,15,17 The TERT promoter mutations were found to be most likely in coexistence with BRAF V600E while the number of cases harboring TERT promoter mutations alone is very rare.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___69', 'num': 69}),\n",
       " Document(page_content='9,17,18 It is still unclear why TERT promoter mutations most likely occur in cooperation with BRAF mutation in the same PTC.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___70', 'num': 70}),\n",
       " Document(page_content='This association was also reported in melanomas 25 and thus suggests that such a relationship between these two oncogenic genetic events may be a general phenomenon in human cancer.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___71', 'num': 71}),\n",
       " Document(page_content='Because of the small number of PTCs with only TERT promoter mutations, it is very difficult to observe any statistical difference between the molecular groups in individual studies.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___72', 'num': 72}),\n",
       " Document(page_content='Therefore, there is a definite need to perform a meta-analysis to overcome the limitation of small sample sizes of individual studies.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___73', 'num': 73}),\n",
       " Document(page_content='Our meta-analysis provided strong evidence that PTCs with coexisting BRAF and TERT promoter mutations were associated with a significantly increased risk for tumor aggressiveness and recurrence when', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___74', 'num': 74}),\n",
       " Document(page_content='compared with PTCs with BRAF or TERT promoter mutation alone.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___75', 'num': 75}),\n",
       " Document(page_content='These findings affirm the hypothesis that BRAF and TERT promoter mutation interaction can enhance the tumor aggressiveness and identify a group of PTCs with the worst clinical course, providing unique', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___76', 'num': 76}),\n",
       " Document(page_content='prognostic and therapeutic implications. There is strong evidence that PTCs harboring BRAF or TERT promoter mutations are associated with increased aggressiveness as compared with wild-type tumors.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___77', 'num': 77}),\n",
       " Document(page_content='23,26 Our results further affirm that the presence of BRAF or TERT alone can increase the tumor aggressiveness when compared to the tumors without both mutations.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___78', 'num': 78}),\n",
       " Document(page_content='From our results, the combination of BRAF and TERT promoter mutations stratifies PTC aggressiveness into distinct subgroups in which the PTCs with concurrent BRAF and TERT promoter mutations exhibit', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___79', 'num': 79}),\n",
       " Document(page_content='the most aggressive clinical course as denoted by this spectrum: BRAF+/TERT+ >> TERT+ only = BRAF+ only >> BRAF-/TERT-.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___80', 'num': 80}),\n",
       " Document(page_content='The comparative aggressiveness of PTCs with TERT promoter mutation only and PTCs with BRAF only are not statistically different, except for the rate of distant metastasis.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___81', 'num': 81}),\n",
       " Document(page_content='This finding can be explained by the fact that BRAF mutation is not associated with distant metastasis in PTCs 27 while PTCs with TERT mutations strongly correlate with increased risk for metastases', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___82', 'num': 82}),\n",
       " Document(page_content='to distant sites. 8 The presence of TERT promoter mutation in PTCs can help clinicians better assess the risk for distant metastasis during follow-up and potentially at presentation. Despite the major', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___83', 'num': 83}),\n",
       " Document(page_content='This article is protected by copyright. All rights reserved.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___84', 'num': 84}),\n",
       " Document(page_content='advances in discovery of thyroid cancer pathogenesis and its potential translational application, the mechanisms by which these mutations interact with each other or contribute to carcinogenesis', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___85', 'num': 85}),\n",
       " Document(page_content='remains to be elucidated. It will take some time to fully understand the underlying mechanisms of this interaction in thyroid cancer.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___86', 'num': 86}),\n",
       " Document(page_content='Besides its association with increased aggressiveness, PTCs with concomitant BRAF and TERT have been reported to be the group with highest risk of recurrence and mortality in recent studies 7,28 and', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___87', 'num': 87}),\n",
       " Document(page_content='help establish a robust role for this oncogenic to identify the small group of PTCs that have highest mortality risk.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___88', 'num': 88}),\n",
       " Document(page_content='This will also add strong motivation for the development of novel targeted therapies targeting both BRAF and TERT promoter mutations.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___89', 'num': 89}),\n",
       " Document(page_content='BRAF and TERT promoter coexistence on clinical outcomes in PTC.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___90', 'num': 90}),\n",
       " Document(page_content='29 A crucial difference from our analysis is that they did not conduct a comparison between groups of PTCs with BRAF+ only and TERT+ only.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___91', 'num': 91}),\n",
       " Document(page_content='Hence, the risk stratification of PTC into four genotypic subgroups cannot be possible with such analysis.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___92', 'num': 92}),\n",
       " Document(page_content='Although there were no significant differences in most of the clinicopathological features between the groups of PTCs with TERT only and PTCs with BRAF only, our findings demonstrated that the', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___93', 'num': 93}),\n",
       " Document(page_content='presence of TERT promoter mutation only can help predict a significant risk for distant metastasis, a fatal event, in PTCs.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___94', 'num': 94}),\n",
       " Document(page_content='Additionally, the authors did not assess the effect of BRAF/TERT coexistence versus BRAF-only or TERT-only on tumor recurrence.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___95', 'num': 95}),\n",
       " Document(page_content='Our study is the second meta-analysis to investigate the interactive effects of BRAF and TERT promoter mutations in PTC and help overcome the limitation of individual studies in which the number of', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___96', 'num': 96}),\n",
       " Document(page_content='cases with TERT promoter mutations alone are very small.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___97', 'num': 97}),\n",
       " Document(page_content='From our results, PTCs with both mutations are associated with the worst clinical course and suggests the value in combining these mutations to better assess patient prognosis and tailor therapeutic', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___98', 'num': 98}),\n",
       " Document(page_content='decision.\\nAs papillary cancer is considered a tumor with a good outcome, 2 identifying the small subset of PTC patients with the most aggressive features becomes of a clinical significance.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___99', 'num': 99}),\n",
       " Document(page_content='This article is protected by copyright. All rights reserved. However, there are some limitations in our studies that need to be addressed.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___100', 'num': 100}),\n",
       " Document(page_content='The first limitation is selection bias in the included studies since all of included studies are retrospective.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___101', 'num': 101}),\n",
       " Document(page_content='Another limitation is that a considerable amount of heterogeneity existed among several metaanalyses, particularly in the comparison of BRAF+/TERT+ versus BRAF+ only.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___102', 'num': 102}),\n",
       " Document(page_content='This probably arises from the differences in the diagnostic criteria of clinicopathological features among pathology centers.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___103', 'num': 103}),\n",
       " Document(page_content='Because of the small number of included studies, we could not perform meta-regression to further explore the origin of the heterogeneity.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___104', 'num': 104}),\n",
       " Document(page_content='In summary, PTCs with concurrent BRAF and TERT promoter mutations are demonstrated to be the most aggressive subgroup of PTC while PTCs with BRAF or TERT alone have less demonstrable aggressiveness.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___105', 'num': 105}),\n",
       " Document(page_content=\"The combination of these mutations helps stratify PTC patients into distinct risk groups and better assess patients' outcome.\", metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___106', 'num': 106}),\n",
       " Document(page_content='Y indicates that the study was evaluated for the corresponding clinicopathological factor; N indicates that the study was not evaluated for the corresponding clinicopathological factor. \\nFIGURE LEGEND', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___107', 'num': 107}),\n",
       " Document(page_content='This article is protected by copyright. All rights reserved.', metadata={'source': 'Prognostic implication of _scp_BRAF__scp_ and _scp_TERT__scp_ promoter mutation combination in papillary thyroid carcinoma_A meta_analysis.json___108', 'num': 108}),\n",
       " Document(page_content='Breast cancer is the leading cause of cancer related death in women.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___1', 'num': 1}),\n",
       " Document(page_content='In spite of its relatively early detection and treatment, distant metastasis to various tissues, including thyroid gland, still remains a challenge.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___2', 'num': 2}),\n",
       " Document(page_content='In general, despite its high vascularization, metastasis to thyroid gland is uncommon (incidence of 0-5% in non-malignant cases to about 24% in malignant cases) and mostly metachronous, as reported in', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___3', 'num': 3}),\n",
       " Document(page_content='series of autopsy studies. [1][2][3][4][5][6][7] Metachronous thyroid metastasis is defined as thyroid metastasis observed at or greater than 6 months after the diagnosis of primary cancer.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___4', 'num': 4}),\n",
       " Document(page_content='Following the pattern, reports of breast cancer metastasizing to thyroid gland are relatively uncommon in clinical practice too; however, breast carcinoma is one of the common primary tumor of thyroid', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___5', 'num': 5}),\n",
       " Document(page_content='metastasis, seen at post-mortem. 8 With this rarity, added with metachronous metastasis nature, particularly many years after the diagnosis of initial tumor, can pose a diagnostic challenge.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___6', 'num': 6}),\n",
       " Document(page_content='Also, as treatment strategies used to treat primary and metastatic thyroid malignancies vary, it becomes essential to appropriately distinguish primary thyroid cancer from metastatic thyroid cancer.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___7', 'num': 7}),\n",
       " Document(page_content=\"In this regard, routine US assessment of thyroid gland, followed by FNAC on suspicion, is part of the breast cancer pa-tients' diagnostic regimen in our hospital through which TM patients are\", metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___8', 'num': 8}),\n",
       " Document(page_content='identified.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___9', 'num': 9}),\n",
       " Document(page_content='The objective of present study was to analyze the ultrasonographic and clinical features of TM condition in breast cancer patients, through which we wish to contribute to the existing understanding of', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___10', 'num': 10}),\n",
       " Document(page_content='this rare condition.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___11', 'num': 11}),\n",
       " Document(page_content='The study was approved by our hospital ethics committee, reference number -IRB-2015-243, who waived the need for informed consent procedure.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___12', 'num': 12}),\n",
       " Document(page_content=\"All the patients' personal identification information was removed before study related usage.\", metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___13', 'num': 13}),\n",
       " Document(page_content='Between 2005 and 2015, routine US analysis of breast cancer patients revealed seven cases with radiographic changes in their thyroid architecture, who underwent US-guided fine-needle aspiration', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___14', 'num': 14}),\n",
       " Document(page_content='cytology (FNAC) confirming TM.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___15', 'num': 15}),\n",
       " Document(page_content='The US-guided FNAC was performed using a 5ml syringe, with 1~2ml negative press, targeting the region that seemed to show the most compact area of sonographically visible microcalcifications or', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___16', 'num': 16}),\n",
       " Document(page_content='nodules, and thus suspicious for malignancy. An eighth case of TM, diagnosed and treated at a different hospital, visited our hospital for follow up, whose data we also considered in this analysis.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___17', 'num': 17}),\n",
       " Document(page_content='The obtained conventional US reports of all patients were performed using the wide-band 5-10 MHz linear probe on a single ultrasound machine (Philips IU22, Philips Medical System, Bothell, WA, USA) by', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___18', 'num': 18}),\n",
       " Document(page_content='three different radiologists with over eight years of experience. The high-resolution images were documented/stored in PACS system.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___19', 'num': 19}),\n",
       " Document(page_content='For the study purpose, to reduce the inter-observer variability, all the images were retrospectively reviewed by a radiologist (>15 years of experience) who was blinded to the clinical, radiological', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___20', 'num': 20}),\n",
       " Document(page_content='and pathological findings.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___21', 'num': 21}),\n",
       " Document(page_content='The US findings were assessed for: echogenicity of thyroid parenchyma, the appearance of the lesions (with mass or without mass), mass details (size, contour, margin, echogenicity, internal structure', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___22', 'num': 22}),\n",
       " Document(page_content='and vascularity) and presence of calcification. Any discrepancy was resolved through discussion with the respective radiologist who provided the prior diagnosis.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___23', 'num': 23}),\n",
       " Document(page_content='Smear slides, prepared from the thyroid gland aspirate, were subject to histological [hematoxylin and eosin (H&E) stain] and immunohistochemical [thyroglobulin (TG) and thyroid transcription factor -1', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___24', 'num': 24}),\n",
       " Document(page_content='(TTF-1)] analysis. FNAC was also performed for \"recurrent foci at chest wall\" which served as a reference standard for cellular morphological assessments.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___25', 'num': 25}),\n",
       " Document(page_content='In addition to the above stains, the thyroid tissue samples obtained from thyroidectomy in 2 patients were subject to immunohistochemical analysis for estrogen receptor (ER) and Progesterone receptor', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___26', 'num': 26}),\n",
       " Document(page_content='(PR). The slides were read by two qualified and experienced (>25 years) pathologists providing their diagnosis.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___27', 'num': 27}),\n",
       " Document(page_content='For the study purpose, the H&E and immunohistochemistry images of all the cases were re-read by a pathologist (>11 years of experience) who was blinded to the prior diagnosis and other patient data.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___28', 'num': 28}),\n",
       " Document(page_content='Any discrepancy was resolved through discussion with the respective pathologist who provided the prior diagnosis.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___29', 'num': 29}),\n",
       " Document(page_content='Clinical records of all the patients were further analyzed for details of the primary condition, interval between primary condition diagnosis and TM, serum thyroid hormone level, primary pathology,', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___30', 'num': 30}),\n",
       " Document(page_content='other associated metastasis, therapeutic strategy undertaken, and survival time after diagnosis.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___31', 'num': 31}),\n",
       " Document(page_content='The study comprised of 8 female patients who were diagnosed with TM from breast cancer between 2005 and 2015. The mean age at the diagnosis of TM was 55.37±9.33 years (range of 43 to 69 years).', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___32', 'num': 32}),\n",
       " Document(page_content='In all the subjects, the condition was symptomless at the time of diagnosis and was suspected of TM during routine US examination.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___33', 'num': 33}),\n",
       " Document(page_content='Clinically, all the subjects had a history of breast cancer and had received treatment for the same. Clinical details of the primary condition are detailed under table 1.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___34', 'num': 34}),\n",
       " Document(page_content='The location of breast cancer of these 8 cases was as follows: right (n=5), left (n=1) and bilateral (n=2).', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___35', 'num': 35}),\n",
       " Document(page_content='The median interval from the diagnosis of breast cancer to detection of TM was 76.5 months (range -6 to 121 months), and thus was labelled as \"metachronous metastasis\" in all the cases.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___36', 'num': 36}),\n",
       " Document(page_content='The details of recurrence/distant metastasis associated with TM, the timeline at which they were diagnosed in respect to TM and their treatment regimen are detailed in table 2.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___37', 'num': 37}),\n",
       " Document(page_content='Briefly, two patients presented with recurrence of the primary condition on the chest wall and were treated with chemotherapy.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___38', 'num': 38}),\n",
       " Document(page_content='Four patients exhibited associated metastasis to other organs/tissues, such as the lungs and lymph nodes (supraclavicular, axillary, cervical and mediastinal lymph nodes).', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___39', 'num': 39}),\n",
       " Document(page_content='Three of these patients received chemotherapy while one underwent thyroidectomy (at a different hospital) for suspected malignant nodule.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___40', 'num': 40}),\n",
       " Document(page_content='The remaining two patients (25%) showed no signs of recurrence or distant metastasis and were treated with partial thyroidectomy (right lobectomy) for one case and total thyroidectomy for the other.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___41', 'num': 41}),\n",
       " Document(page_content='One patient, who showed distant metastases to cervical and mediastinal lymph nodes, also presented with a history of hyperthyroidism and showed slightly elevated serum thyroxine (T4) level (182 nmol/', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___42', 'num': 42}),\n",
       " Document(page_content='ml).', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___43', 'num': 43}),\n",
       " Document(page_content='The survival time of patients was considered from the date of their TM diagnosis to the completion of this study or till the patient died , whichever happened earlier (table 2).', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___44', 'num': 44}),\n",
       " Document(page_content='Two recurrence patients with foci on the chest wall received chemotherapy and were alive at 14 and 5 months, respectively, from the date of their TM diagnosis.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___45', 'num': 45}),\n",
       " Document(page_content='Of the four patients who exhibited distant metastasis, 3 received chemotherapy of which one patient died at 21', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___46', 'num': 46}),\n",
       " Document(page_content='The thyroid gland has an affluent blood supply of about 560 mL/100 g tissue/min, which is second only to the adrenal gland.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___47', 'num': 47}),\n",
       " Document(page_content='Yet, thyroid metastasis from the cancer of extra-thyroid origin is infrequent, 9 and the reason for this is not clear.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___48', 'num': 48}),\n",
       " Document(page_content='Chung et al., found that the abnormal thyroid conditions like goiter increases the probability of TM, which may be due to alteration in local homeostasis resulting in decreased oxygen and iodine', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___49', 'num': 49}),\n",
       " Document(page_content='content. 7,10,11 In the present study, 2/8 cases showed such associated thyroid pathology; goiter and hyperthyroidism.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___50', 'num': 50}),\n",
       " Document(page_content='TM is usually observed in elderly individuals in their sixth and seventh decades of life.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___51', 'num': 51}),\n",
       " Document(page_content='12,13 Data from the present study revealed a mean age of 55.4 years which is slightly younger than that presented in the literature.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___52', 'num': 52}),\n",
       " Document(page_content='As per autopsy reports, the incidence of TM in patients who die as a result of malignancy is up to 24%.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___53', 'num': 53}),\n",
       " Document(page_content='14 The prevalence of thyroid nodules ranges from 20-67%, and the incidence of malignant nodules is about 0.45-13%.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___54', 'num': 54}),\n",
       " Document(page_content='15 In recent years the reports of TM cases has been gradually increasing, which may be related to more frequent thyroid imaging and FNAC studies in cancer patients.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___55', 'num': 55}),\n",
       " Document(page_content='[16][17][18] Most common sites of primary tumors are renal cell carcinoma, breast cancer and lung cancer, however, there is no complete agreement as to which cancer most frequently metastasize to the', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___56', 'num': 56}),\n",
       " Document(page_content='thyroid as it may depend on many factors such as epidemiology and clinical behavior of the primary cancer and diagnostic methods used.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___57', 'num': 57}),\n",
       " Document(page_content='8 TM from renal cell carcinoma is usually symptomatic, where the patients present with symptoms such as a new neck mass, dysphagia and hoarseness, while that from lung and breast cancer may go', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___58', 'num': 58}),\n",
       " Document(page_content='symptomless.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___59', 'num': 59}),\n",
       " Document(page_content='8 A study described an unusual case of thyroid metastasis from breast carcinoma, characterized by massive intra-arterial embolization and clinically presented as acute thyroiditis, which is uncommon.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___60', 'num': 60}),\n",
       " Document(page_content='19 Also TM can present as a synchronous ormetachronous manifestation of known primary tumors or a first finding of unknown primary tumor (occult primary neoplasm).', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___61', 'num': 61}),\n",
       " Document(page_content='[20][21][22][23] All TM patients in our study were symptomless, demonstrated metachronous metastasis, and were discovered during routine US imaging procedures.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___62', 'num': 62}),\n",
       " Document(page_content='Several studies have assessed the usefulness of US in predicting thyroid cancer, while characterizing its features, and recommend US evaluation as a good modality for early detection of thyroid cancer', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___63', 'num': 63}),\n",
       " Document(page_content='.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___64', 'num': 64}),\n",
       " Document(page_content='[24][25][26][27] Given the cost effectiveness of this non-invasive diagnostic tool, the inclusion of US analysis in routine follow-up of breast cancer patients could be of use in early detection of', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___65', 'num': 65}),\n",
       " Document(page_content='thyroid metastasis.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___66', 'num': 66}),\n",
       " Document(page_content='Ultrasound plays an important role in screening thyroid disease and making a differential diagnosis of benign and malignant tumors.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___67', 'num': 67}),\n",
       " Document(page_content='US features of malignant thyroid nodules in general and of primary thyroid cancer and thyroid metastasis in particular are detailed elsewhere.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___68', 'num': 68}),\n",
       " Document(page_content='28,29 Although no single mentioned feature is decisive for malignant thyroid condition, presence of a combination of two or more of these features increases the chances of malignancy.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___69', 'num': 69}),\n",
       " Document(page_content='In our study, two TM samples appeared as classical Primary Thyroid Cancer (PTC), while six patients showed heterogenous thyroid parenchyma with diffuse calcifications without nodule, which is rare in', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___70', 'num': 70}),\n",
       " Document(page_content='TM conditions. Hence it becomes important to consider the possibility of metastasis from elsewhere while diagnosing new thyroid masses in patients with a previous history of malignancy.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___71', 'num': 71}),\n",
       " Document(page_content='But it is difficult to differentiate between PTC and TM using US only.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___72', 'num': 72}),\n",
       " Document(page_content='US guided FNAB/FNAC is of value in such conditions whose accuracy for TM diagnosis from breast cancer is reportedly 90.8% to 91.2%.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___73', 'num': 73}),\n",
       " Document(page_content='30 In this regard, if malignant cells are present in a thyroid FNAB and primary malignancy is not a consideration, then clinical history consideration with immunohistochemical analysis is essential', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___74', 'num': 74}),\n",
       " Document(page_content='for accurate diagnosis.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___75', 'num': 75}),\n",
       " Document(page_content='The interval from a non-thyroid primary cancer diagnosis to TM diagnosis varies from a few months in aggressive malignancies, to many years in less aggressive condition, the median of which was', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___76', 'num': 76}),\n",
       " Document(page_content='reported as 53 months. 7 The same was found to be 76.5 months (median interval) in our study which is considerably higher than the reported value.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___77', 'num': 77}),\n",
       " Document(page_content='Additional findings from our study reveal that the location of primary source, including bilateral breast cancer condition, has no association with the probability of occurrence of TM.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___78', 'num': 78}),\n",
       " Document(page_content='The metachronosity of thyroid metastasis from breast cancer can be as long as 12 years from the diagnosis of the primary condition.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___79', 'num': 79}),\n",
       " Document(page_content='31 In the present study, one of our patients presented to the hospital with TM, more than 10 years after she was diagnosed and treated for breast cancer.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___80', 'num': 80}),\n",
       " Document(page_content='Such durations can be long enough to miss the past diagnosis/treatment of malignant disease thus demanding extra attention in the history.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___81', 'num': 81}),\n",
       " Document(page_content='Numerous case reports have suggested that metastases to the thyroid gland are associated with poor prognosis, 6,32 while others report that it does not seem to worsen the outcome when compared to', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___82', 'num': 82}),\n",
       " Document(page_content='other associated distant metastasis conditions. 33 Few studies have assessed the effectiveness of the therapy for TM from breast cancer condition.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___83', 'num': 83}),\n",
       " Document(page_content='In agreement with Ishikawa et al., we found that thyroidectomy in an isolated TM condition, with controlled primary tumor, may result in prolonged disease-free survival with no difference in survival', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___84', 'num': 84}),\n",
       " Document(page_content='time amongst total and partial thyroidectomy. 16 But, total thy-roidectomy was not effective in prolonging the life of a patient with lung metastasis.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___85', 'num': 85}),\n",
       " Document(page_content='Chemotherapy is the treatment of choice in such patients with widespread distant metastatic condition.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___86', 'num': 86}),\n",
       " Document(page_content='In the present study chemotherapy demonstrated shrinkage in the calcifications with a change in thyroid parenchyma from being heterogeneous to homogenous in four of five distant metastasis patients.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___87', 'num': 87}),\n",
       " Document(page_content='Hence, our supposition is that for the controlled primary tumor condition, with no associated relapse or distant metastasis, thyroidectomy may form the treatment of choice in terms of disease free', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___88', 'num': 88}),\n",
       " Document(page_content='survival; while for the widespread metastatic condition the TM may respond well to the administered chemotherapy, thus eliminating the need for thyroidectomy.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___89', 'num': 89}),\n",
       " Document(page_content='Due to the rarity of the condition, the present study is limited by the number of patients assessed, which is not large enough to represent the population of breast cancer patients with TM.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___90', 'num': 90}),\n",
       " Document(page_content='A long term follow-up is also desirable to assess the treatment (thyroidectomy/chemotherapy) value in long-term disease free survival. Such studies are further warranted.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___91', 'num': 91}),\n",
       " Document(page_content='The infrequent, possibly metachronous and asymptomatic nature of TM from extra-thyroid origin, makes it a challenging condition to be diagnosed in a clinical setting.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___92', 'num': 92}),\n",
       " Document(page_content='With breast cancer being one of the most common primary tumor exhibiting TM, a routine examination of the thyroid gland is essential in such patients.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___93', 'num': 93}),\n",
       " Document(page_content='In this regards, the US analysis may serve as the screening tool of choice, owing to its non-invasive nature and cost effectiveness.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___94', 'num': 94}),\n",
       " Document(page_content='None the less, it is difficult to differentiate between PTC and TM using US alone, during which US guided FNAB/ FNAC is of value in obtaining a more accurate diagnosis.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___95', 'num': 95}),\n",
       " Document(page_content='Thyroidectomy, both partial and total, could be the treatment of choice in a controlled primary tumor condition, with no associated relapse or distant metastasis; while in a widespread metastatic', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___96', 'num': 96}),\n",
       " Document(page_content='condition the TM may respond well to the chemotherapy, and thus may eliminate the need for thyroidectomy.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___97', 'num': 97}),\n",
       " Document(page_content='We declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work, there is no professional or other personal interest of', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___98', 'num': 98}),\n",
       " Document(page_content='any nature or kind in any product, service and/or company that could be construed as influencing the position presented in, or the review of, the manuscript entitled.', metadata={'source': 'Breast cancer metastasis to thyroid_ a retrospective analysis.json___99', 'num': 99}),\n",
       " Document(page_content='The incidence of thyroid carcinoma has been increasing more rapidly than other cancers in recent decades, [1] largely because of the growing use of sensitive diagnostic tools, such as highresolution', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___1', 'num': 1}),\n",
       " Document(page_content='ultrasound and fine-needle aspiration biopsy.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___2', 'num': 2}),\n",
       " Document(page_content='[2][3][4] Among thyroid carcinomas, papillary thyroid cancer (PTC), the most common histotype (>85% of all registered cases), is largely responsible for the increased rates of thyroid cancer.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___3', 'num': 3}),\n",
       " Document(page_content='[5] Although, it is suggested to be an indolent disease with a favorable prognosis, some tumors with certain clinicopathological features can still show aggressive behavior with poor prognosis.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___4', 'num': 4}),\n",
       " Document(page_content='[6,7] Papillary thyroid cancer often presents with multifocal tumors and unilateral or bilateral multifocal PTC is not rare.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___5', 'num': 5}),\n",
       " Document(page_content='Clinically, the presence of ≥2 anatomically separated foci in the thyroid gland is defined as multifocal PTC; it most often presents as multiple microcarcinomas (maximum size of tumor 10 mm) and', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___6', 'num': 6}),\n",
       " Document(page_content='occasionally has visible lesions.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___7', 'num': 7}),\n",
       " Document(page_content='[8] Multifocality may arise from intrathyroidal metastases from a single malignant clone, as well as multiple independent origins accompanied by intrathyroidal metastasis.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___8', 'num': 8}),\n",
       " Document(page_content='[9] The reported prevalence of multifocal PTC ranges from 18% to 87% depending on epidemiological and methodological factors.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___9', 'num': 9}),\n",
       " Document(page_content='[10] It is well-established that PTC has a strong predilection for lymph node metastasis, most commonly to the central neck compartment (level VI) which are bordered by the hyoid bone superiorly,', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___10', 'num': 10}),\n",
       " Document(page_content='suprasternal notch inferiorly, and the carotid sheaths laterally. [11] Approximately, 30% to 90% of patients with PTC will have clinical or occult cervical lymph node involvement.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___11', 'num': 11}),\n",
       " Document(page_content='[12] However, cervical lymph node involvement characteristics and risk factors in multifocal PTC are rarely mentioned.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___12', 'num': 12}),\n",
       " Document(page_content='Accordingly, a retrospective analysis was performed to identify risk factors and lymph node metastasis characteristics in multifocal PTC that expect to inform clinical decision-making.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___13', 'num': 13}),\n",
       " Document(page_content='This article mainly focuses on the association of multifocal PTC with central lymph node metastasis.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___14', 'num': 14}),\n",
       " Document(page_content='We conducted a retrospective analysis.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___15', 'num': 15}),\n",
       " Document(page_content='The medical records of PTC patients (N = 1249) who underwent thyroidectomy plus lymph node dissection at the department of Thyroid and Parathyroid Surgery Center, West China Hospital of Sichuan', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___16', 'num': 16}),\n",
       " Document(page_content='University, between January 1, 2015 and December 31, 2015, were reviewed.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___17', 'num': 17}),\n",
       " Document(page_content='Preoperative fine-needle aspiration biopsy and postoperative specimen were reviewed by 2 experienced pathologists in a blind fashion, who confirmed the diagnosis of PTC and the number of tumor foci.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___18', 'num': 18}),\n",
       " Document(page_content='Patients who performed total thyroidectomy plus bilateral central neck dissection and identified with multifocal tumors from 18 to 80 years were selected (N = 285).', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___19', 'num': 19}),\n",
       " Document(page_content='Meanwhile, an equal number of solitary PTC patients were chosen for comparison using a random number table.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___20', 'num': 20}),\n",
       " Document(page_content='Those who undergone less-than-total thyroidectomy cases, unilateral central neck dissection and had ever neck surgery, radiation exposure, a definite or suspected family history of PTC, and incomplete', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___21', 'num': 21}),\n",
       " Document(page_content='medical records were not included. [13] In present study, for multifocal tumors, the tumor with the maximum diameter was considered the primary tumor.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___22', 'num': 22}),\n",
       " Document(page_content=\"Data on the patients' clinical features (sex, age at diagnosis), tumor histological characteristics (maximum size of tumor, solitary or multifocal foci, Hashimoto thyroiditis, capsular invasion,\", metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___23', 'num': 23}),\n",
       " Document(page_content='extrathyroidal extension, pathological tumor stage), distant metastasis at diagnosis, radioactive iodine ablation, radioactive iodine ablation dose (mCi), local or distant recurrence, and died of', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___24', 'num': 24}),\n",
       " Document(page_content='thyroid cancer were extracted from the database.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___25', 'num': 25}),\n",
       " Document(page_content='Local or distant recurrence was diagnosed by metastatic lymph node or newly detected tumor >6 months after the initial operation as confirmed by imageological examination (mainly ultrasonography) or', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___26', 'num': 26}),\n",
       " Document(page_content='fine-needle aspiration biopsy. [14] The follow-up time of study population was 12 to 26 months, and mean time was 18.7 months.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___27', 'num': 27}),\n",
       " Document(page_content='The histologic diagnosis was classified according to World Health Organization system. Tumor classification was standardized using the TNM system of the American Joint Committee on cancer (version 7).', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___28', 'num': 28}),\n",
       " Document(page_content='Univariate and multivariate analyses were performed, concentrating on risk factors and central neck compartment involvement characteristics in multifocal PTC.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___29', 'num': 29}),\n",
       " Document(page_content='Statistical analysis was performed using SAS9.3.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___30', 'num': 30}),\n",
       " Document(page_content='(SAS institute Inc, Cary, NC) Continuous variables with normal distribution are expressed as the mean ± standard deviation, and continuous variables without normal distribution are expressed as', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___31', 'num': 31}),\n",
       " Document(page_content=\"medians. Categorical variables are presented as numbers. Continuous variables with normal distribution were compared using Student's sample t test or analysis of variable.\", metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___32', 'num': 32}),\n",
       " Document(page_content='Categorical variables were compared using the chi-square test or Fisher exact chi-square test. A level of 5% was used to identify significant relationships.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___33', 'num': 33}),\n",
       " Document(page_content=\"Independent predictors were determined by multivariable cox's regression model based on the risk factors related to multifocality and central lymph node metastasis.\", metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___34', 'num': 34}),\n",
       " Document(page_content='P < .05 with a 95% confidence interval indicated statistical significance.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___35', 'num': 35}),\n",
       " Document(page_content='Clinical and pathological factors that could be associated with multifocality were investigated in this present study, including age, sex, body mass index (BMI), Hashimoto thyroiditis, capsular', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___36', 'num': 36}),\n",
       " Document(page_content='invasion, extrathyroidal extension, size of the largest focus, pathological T classification, pathological N+ stage, TNM stage, distant metastasis at diagnosis, local or distant recurrence,', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___37', 'num': 37}),\n",
       " Document(page_content='radioactive iodine ablation (RAI), RAI dose (mCi), died of thyroid cancer.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___38', 'num': 38}),\n",
       " Document(page_content='No significant differences were found between the solitary and multifocality group in sex, height (cm), weight (kg), BMI (kg/m 2 ), distant metastasis or distant recurrence, RAI dose (mCi), died of', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___39', 'num': 39}),\n",
       " Document(page_content='thyroid cancer, etc. (all P > .05; Table 1).', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___40', 'num': 40}),\n",
       " Document(page_content='Of the patients, however, a statistically differences were showed in the presence of autoimmune thyroid disease (76 vs 51), capsular invasion (226 vs As identified in the univariate analysis, 6', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___41', 'num': 41}),\n",
       " Document(page_content='significant factors: Hashimoto thyroiditis, capsular invasion, extrathyroidal extension, size of the largest focus >10 mm, advanced pathological T classification, and N+ stage presented a higher', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___42', 'num': 42}),\n",
       " Document(page_content='positive rate in multifocal PTC.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___43', 'num': 43}),\n",
       " Document(page_content='To determine how strongly those factors were associated with multifocality, the multivariable Cox regression model was performed for these 6 factors, which further showed that not autoimmune thyroid', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___44', 'num': 44}),\n",
       " Document(page_content='disease (HR, 1.078; 95% CI, 0.762-1.589), extrathyroidal extension (HR, 1.367; 95% CI, 0.826-2.263), and size of the largest focus >10 mm (HR, 1.174; 95% CI, 0.808-1.707) but capsular invasion (HR,', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___45', 'num': 45}),\n",
       " Document(page_content='1.589; 95% CI, 1.352-1.984), advanced pathological T classification (HR, 3.582; 95% CI, 2.184-5.870), and pathological N+ stage (HR, 1.872; 95% CI, 1.278-2.742) were related to increased risk of', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___46', 'num': 46}),\n",
       " Document(page_content='multifocality (P < .05; Table 2).', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___47', 'num': 47}),\n",
       " Document(page_content='Pathologically positive lymph node metastasis was significantly much more common in the multifocal PTC group than in the solitary group (201; 70.5% vs 144; 50.5%; Table 1).', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___48', 'num': 48}),\n",
       " Document(page_content='In previous studies, lymph node metastasis characteristics in multifocal PTC were rare mentioned. Therefore, the effect of the multifocal PTC on level VI lymph node metastasis was further examined.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___49', 'num': 49}),\n",
       " Document(page_content='The association was investigated between several relevant clinical and pathological factors pertaining to the patient and disease, with level VI lymph node metastasis in this present study by', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___50', 'num': 50}),\n",
       " Document(page_content='univariate analysis.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___51', 'num': 51}),\n",
       " Document(page_content='Certain baseline demographics and tumor characteristics, such as increasing age, BMI, Hashimoto thyroiditis, size of the largest focus >10 mm, and clinical T classification were not significantly', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___52', 'num': 52}),\n",
       " Document(page_content='associated with central lymph node positivity in the study population (P > .05; Table 3).', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___53', 'num': 53}),\n",
       " Document(page_content='However, according to the pathological evaluation, significant differences of central neck compartment involvement were observed on male sex, multifocality, capsular invasion, extrathyroidal extension', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___54', 'num': 54}),\n",
       " Document(page_content=', and advanced pathological T classification (all P < .05; Table 3).', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___55', 'num': 55}),\n",
       " Document(page_content='The hazard ratio (HR) for VI lymph node metastasis was identified by Cox proportional hazards regression model based on the above mentioned factors.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___56', 'num': 56}),\n",
       " Document(page_content='Controlling for male sex, multifocality, capsular invasion, extrathyroidal extension, and advanced T classification, the HR with capsular invasion and extrathyroidal extension were 1.309 and 1.247,', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___57', 'num': 57}),\n",
       " Document(page_content='respectively, and this discrepancy did not reach a statistically significant difference (P > .05; Table 3).', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___58', 'num': 58}),\n",
       " Document(page_content='However, there was a significant increased HR for central neck compartment involvement in male sex (HR, 2.694; 95% CI, 1.740-4.169), advanced pathological T classification (HR, 2.403; 95% CI, 1.479-', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___59', 'num': 59}),\n",
       " Document(page_content='3.907), and multifocality (HR, 1.988; 95% CI, 1.361-2.906) (all P < .05; Table 3).', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___60', 'num': 60}),\n",
       " Document(page_content='Papillary thyroid cancer (PTC) is the most common histotype of thyroid malignancy, with a strong predilection for lymph node metastasis, most commonly to the central neck compartment (level VI).', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___61', 'num': 61}),\n",
       " Document(page_content='[11] In previous study, few studies assessed lymph node metastasis in multifocal PTC. It is generally believed that PTC is an indolent cancer with an excellent prognosis and a low mortality rate.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___62', 'num': 62}),\n",
       " Document(page_content='It should not be overtreated.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___63', 'num': 63}),\n",
       " Document(page_content='Indeed, the current 30-year overall survival rates of total/near-total thyroidectomy PTC patients with or without radioiodine ablation therapy are >90%, [15] but there is still a report of patient', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___64', 'num': 64}),\n",
       " Document(page_content='with lethal case fulminant mPTC.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___65', 'num': 65}),\n",
       " Document(page_content='[16] In present study, multifocality was associated with higher rates of disease recurrence and poorer prognosis compared with unifocal disease, in accordance with previous studies.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___66', 'num': 66}),\n",
       " Document(page_content='[6,17] Multifocality has been reported in 18% to 87% of patients with PTC [10] and was observed in 22.8% of the patients in our center in 2015.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___67', 'num': 67}),\n",
       " Document(page_content='The incidence of lymph node involvement solitary PTC is approximately 50%.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___68', 'num': 68}),\n",
       " Document(page_content='Because of its higher propensity for lymph node metastasis, multifocal PTC  may have a higher lymph nodes metastasis rate of >50%.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___69', 'num': 69}),\n",
       " Document(page_content='In our study population, 285 patients had multifocality, and 201 of these patients identified lymph node metastasis. The incidence of central lymph node involvement reached 70.5%.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___70', 'num': 70}),\n",
       " Document(page_content='Due to the indolent nature of PTC, whether lymph node metastasis is a poor prognostic factor remains controversial. Several studies have treated lymph node metastasis as a sign of poor prognosis.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___71', 'num': 71}),\n",
       " Document(page_content='[18][19][20][21] Other reports, however, suggest that lymph nodes positivity has no long-term influence on patient prognosis.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___72', 'num': 72}),\n",
       " Document(page_content='[22,23] One factor that is well-established and widely adopted is that lymph node metastasis has a strong association with recurrence.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___73', 'num': 73}),\n",
       " Document(page_content='[24] Therefore, risk factors and tumor metastasis to the neck compartment in multifocal PTC were investigated.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___74', 'num': 74}),\n",
       " Document(page_content='In this present study, multifocality showed a higher positive rate of Hashimoto thyroiditis, capsular invasion, extrathyroidal extension, tumor size >10 mm, advanced p T classification, p N+ stage,', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___75', 'num': 75}),\n",
       " Document(page_content='local recurrence, RAI. There is a significant association between capsular invasion, advanced pathological T classification, N+ stage, and multifocal PTC by multivariable Cox regression model.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___76', 'num': 76}),\n",
       " Document(page_content='Meanwhile, univariate and multivariate analysis of the clinical and pathological factors associated with central lymph node metastasis showed that multifocality was one of independent risk factors for', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___77', 'num': 77}),\n",
       " Document(page_content='level VI lymph node metastasis. Multifocality increases risk of metastasis to the central neck compartment in PTC.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___78', 'num': 78}),\n",
       " Document(page_content='The 2009 Revised American Thyroid Association (ATA) recommends therapeutic level VI dissections in patients with clinical evidence of lymph node involvement.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___79', 'num': 79}),\n",
       " Document(page_content='[25] However, the role for prophylactic level VI lymph node dissection remains largely controversial.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___80', 'num': 80}),\n",
       " Document(page_content='[26] Approximately, 30% to 90% of patients with PTC will have clinical or occult cervical lymph node involvement.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___81', 'num': 81}),\n",
       " Document(page_content='[12] Prophylactic central neck dissection increase the risk of postoperative complications, mainly hypoparathyroidism and laryngeal nerve injury.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___82', 'num': 82}),\n",
       " Document(page_content='[27] Therefore, some studies have recommended that prophylactic central neck dissection should only be considered in patients with high risk factors, such as male patients, younger patients, and those', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___83', 'num': 83}),\n",
       " Document(page_content='with larger tumor sizes and extrathyroidal extensions.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___84', 'num': 84}),\n",
       " Document(page_content='[28] However, prophylactic central neck dissection makes it possible for us to accurately assess the stage of tumors postoperation for evaluating the necessity of radioactive iodine therapy [28] ;', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___85', 'num': 85}),\n",
       " Document(page_content='there is an increased risk of complications in second operation when the tumor recurs in the central compartment.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___86', 'num': 86}),\n",
       " Document(page_content='[29] Importantly, prophylactic central neck dissection actually is relatively safe in the hands of an experienced surgeon and it can prevents recurrence and improves tumor-free or overall survival', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___87', 'num': 87}),\n",
       " Document(page_content='effectively due to removal of microscopic metastases in the central compartment lymph node. [30] Like any other, this study has its limitations.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___88', 'num': 88}),\n",
       " Document(page_content='Because this was a retrospective review, the data were retrospectively collected and analyzed. The selection of single patients may generate a selection bias.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___89', 'num': 89}),\n",
       " Document(page_content='Furthermore, the sample size was not sufficiently large as only 570 patients were ultimately identified. Studies with larger sample sizes are needed to further confirm our predictive model.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___90', 'num': 90}),\n",
       " Document(page_content=\"In addition, in Wang et als' study, [26] the insular histotype identified more poor prognosis and in Wang et als' study, [31] patients with tall cell variant of PTC is more aggression than classic PTC\", metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___91', 'num': 91}),\n",
       " Document(page_content=', being associated with increased incidence of multifocality, extrathyroidal extension, lymph node involvement, distant metastasis, and recurrence.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___92', 'num': 92}),\n",
       " Document(page_content='The association of the subtype of PTC, such as follicular variant, diffuse sclerosing, insular, tall cell variant, columnar, etc., with multifocality and central lymph node metastasis did not conduct', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___93', 'num': 93}),\n",
       " Document(page_content='further exploration because of lacking a further subdivision of PTC in our institution.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___94', 'num': 94}),\n",
       " Document(page_content='Lalmi et al [32] suggest that the promising perspective applied to diagnosis and prediction of thyroid cancer lies in molecular biology test, however, gene mutation (BRAF, RAS, RET, TERT), gene', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___95', 'num': 95}),\n",
       " Document(page_content='rearrangements (RET/PTC), and immuno-histochemical markers were considered only the FNAB cannot give definite diagnosis at our center, the predictors of molecular biology also need further delineation', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___96', 'num': 96}),\n",
       " Document(page_content='.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___97', 'num': 97}),\n",
       " Document(page_content='Taken together, multifocality was associated with more aggressive and poorer prognosis.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___98', 'num': 98}),\n",
       " Document(page_content='Capsular invasion, advanced pathological T classification and N+ stage were independent predictors of multifocal PTC.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___99', 'num': 99}),\n",
       " Document(page_content='Total thyroidectomy with prophylactic bilateral central lymph node dissection should be recommended during surgery in multifocal PTC due to a higher propensity for level VI lymph node metastasis.', metadata={'source': 'Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.json___100', 'num': 100}),\n",
       " Document(page_content='surgery was used as the primary management strategy for PTL.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___1', 'num': 1}),\n",
       " Document(page_content='Since the introduction of effective chemotherapeutic regimens, however, the treatment paradigm for PTL has now changed and is based on histological subtype.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___2', 'num': 2}),\n",
       " Document(page_content='The mainstay of treatment is combined modality therapy (CMT) for aggressive lymphoma and RT for localized indolent lymphoma.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___3', 'num': 3}),\n",
       " Document(page_content='Although a large-scale study has been published, it did not focus on the recent treatment of PTL (Zinzani et al, 1999;Derringer et al, 2000), namely CMT.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___4', 'num': 4}),\n",
       " Document(page_content='A recent retrospective study from the Rare Cancer Network involving 87 patients focused on the treatment of PTL (Onal et al, 2010).', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___5', 'num': 5}),\n",
       " Document(page_content='It reported that CMT improved the prognosis of patients with aggressive lymphoma, although the role of CMT in those with indolent lymphoma is still uncertain.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___6', 'num': 6}),\n",
       " Document(page_content='Thus, larger studies are needed to further investigate the optimal treatment of PTL.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___7', 'num': 7}),\n",
       " Document(page_content=\"Ito Hospital is one of the largest specialized hospitals for thyroid disease in Japan, with 2511 patients having visited the hospital for first-time consultations regarding Hashimoto's disease in 2004\", metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___8', 'num': 8}),\n",
       " Document(page_content='.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___9', 'num': 9}),\n",
       " Document(page_content='In this study, we re-evaluated the clinicopathological features of PTL in the largest-scale, single-institutional study ever to describe the clinical features and treatment outcomes of PTL in detail.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___10', 'num': 10}),\n",
       " Document(page_content=\"Also, 24 553 patients who were diagnosed with Hashimoto's disease at Ito Hospital were reviewed and the incidence of PTL among Hashimoto's disease was explored.\", metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___11', 'num': 11}),\n",
       " Document(page_content='Between January 1990 and December 2004, 186 patients were diagnosed with PTL at Ito Hospital (Tokyo, Japan).', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___12', 'num': 12}),\n",
       " Document(page_content='PTL is defined as a lymphoma developing in the thyroid gland with or without involvement of regional lymph nodes or other visceral tissues (Derringer et al, 2000).', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___13', 'num': 13}),\n",
       " Document(page_content='In this study, stage IE patients (n = 55) had localized involvement of the thyroid alone, whereas in stage IIE patients (n = 116) the major site of involvement was the thyroid gland, with associated', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___14', 'num': 14}),\n",
       " Document(page_content='regional lymph node involvement.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___15', 'num': 15}),\n",
       " Document(page_content='Of the 186 patients, four patients with stage IIIE, 10 patients with stage IVE and one patient whose stage was uncertain were excluded, as in the study by the Rare Cancer Network (Onal et al, 2010),', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___16', 'num': 16}),\n",
       " Document(page_content='because the primary site of their lymphoma was uncertain. Subsequently, PTL was diagnosed in 171 patients and their medical, pathological and radiological reports were retrospectively reviewed.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___17', 'num': 17}),\n",
       " Document(page_content='All patients were diagnosed based on histological examination of thyroid tissue specimens.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___18', 'num': 18}),\n",
       " Document(page_content='The clinical stage was evaluated by ultrasonography (n = 170), computed tomography (n = 167), 67 Ga-citrate-scintigraphy (n = 164) and bone marrow aspiration biopsy (n = 160), with the aid of proposed', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___19', 'num': 19}),\n",
       " Document(page_content='criteria (Lister et al, 1989).', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___20', 'num': 20}),\n",
       " Document(page_content=\"During the same time period, 24 553 patients were diagnosed with Hashimoto's disease at Ito Hospital.\", metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___21', 'num': 21}),\n",
       " Document(page_content=\"The diagnosis of Hashimoto's disease was based on the presence of elevated anti-thyroid peroxidase antibody and/or anti-thyro-globulin antibody, regardless of the thyroid function.\", metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___22', 'num': 22}),\n",
       " Document(page_content=\"Patients without these antibodies were also diagnosed with Hashimoto's disease based on positive pathological findings.\", metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___23', 'num': 23}),\n",
       " Document(page_content='Follow-up data were calculated from the time of initial surgery on the thyroid gland to the last follow-up.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___24', 'num': 24}),\n",
       " Document(page_content='The clinical follow-up was obtained from patient records, oral communication with the patients and their families and communication with the referring physicians.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___25', 'num': 25}),\n",
       " Document(page_content='This study was approved by the institutional review board of Ito Hospital.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___26', 'num': 26}),\n",
       " Document(page_content='An expert hematopathologist and an expert thyroid pathologist conducted a pathological review of the biopsy specimens obtained from the 171 patients.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___27', 'num': 27}),\n",
       " Document(page_content='Paraffin blocks were available from 170 of 171 patients. All specimens were re-immunostained for CD5, CD10, CD20, BCL2, BCL6, MUM1 and Ki-67.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___28', 'num': 28}),\n",
       " Document(page_content='In addition, several T-cell markers and cyclinD1 were added to some specimens if needed.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___29', 'num': 29}),\n",
       " Document(page_content='The specimens were classified with according to the World Health Organization classification (Harris et al, 2000).', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___30', 'num': 30}),\n",
       " Document(page_content='The presence of lymphocytic thyroiditis, defined in this study as reactive lymphocytic or lymphoplasmacytic infiltrates in the thyroid parenchyma with formation of lymphoid aggregates and fibrosis,', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___31', 'num': 31}),\n",
       " Document(page_content='was investigated in all 170 patients for whom paraffin blocks were available.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___32', 'num': 32}),\n",
       " Document(page_content='Primary thyroid B-cell lymphomas other than DLBCL with follicular lymphoma, peripheral T-cell lymphoma and plasmacytoma were pathologically classified into three groups: DLBCL, DLBCL with MALT', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___33', 'num': 33}),\n",
       " Document(page_content='lymphoma and MALT lymphoma (Fig 1). According to the decision tree proposed by Hans et al (2004), the 63 patients with DLBCL were assigned to two groups based on expression of CD10, BCL6 and MUM1.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___34', 'num': 34}),\n",
       " Document(page_content='Patients with CD10+ or CD10-BCL6 + MUM1-type were classified as germinal centre B-cell-like (GCB) type, and the others were classified as non-GCB type.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___35', 'num': 35}),\n",
       " Document(page_content='At Ito Hospital, treatment for PTL was based primarily on the clinical stage; RT alone was given for stage IE and CMT was given for stage IIE PTL.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___36', 'num': 36}),\n",
       " Document(page_content='The surgical role was mainly for biopsies; excision biopsy was performed in 146 patients, and subtotal or total thyroidectomy was performed in 23 and two patients respectively.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___37', 'num': 37}),\n",
       " Document(page_content='CMT usually included RT and multiple courses of CHOP (CHOP: cyclophosphamide 750 mg/m 2 , adriamycin 40 mg/m 2 , vincristine 1AE4 mg/m 2 , and prednisolone 100 mg/body) based chemotherapy.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___38', 'num': 38}),\n",
       " Document(page_content='RT encompassed the whole of the neck and the upper mediastinum. No patients were treated with rituximab.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___39', 'num': 39}),\n",
       " Document(page_content='A relapse of PTL was defined as the involvement of new sites, recurrence in originally involved sites or more than a 25% increase in the size of the original tumour masses.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___40', 'num': 40}),\n",
       " Document(page_content='A complete response was defined by the disappearance of all documented disease. A partial response was defined by a reduction of at least 50% in the largest diameter of every measurable lesion.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___41', 'num': 41}),\n",
       " Document(page_content='The data were analyzed as of August 2008. The probabilities of overall survival (OS) and event-free survival (EFS) were estimated by the Kaplan-Meier method.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___42', 'num': 42}),\n",
       " Document(page_content='OS was calculated from the time of initial surgery on the thyroid gland to death from any cause and EFS was defined as the time from initial surgery on the thyroid gland to the absence of at least a', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___43', 'num': 43}),\n",
       " Document(page_content='partial response on the intermediate evaluation, relapse or death in remission.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___44', 'num': 44}),\n",
       " Document(page_content='For analysis of OS, data on patients who were alive at the last follow-up contact were censored.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___45', 'num': 45}),\n",
       " Document(page_content='For the analysis of EFS, data on patients who were alive without any progression of the primary disease at the last follow-up were censored.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___46', 'num': 46}),\n",
       " Document(page_content=\"Associations between potential prognostic factors and outcomes were evaluated using Cox's proportional hazards regression models.\", metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___47', 'num': 47}),\n",
       " Document(page_content='The following variables were considered covariates: age at diagnosis, sex, clinical symptoms (rapid enlargement of goitre within 3 months, hoarseness and dyspnoea), laboratory findings [lactate', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___48', 'num': 48}),\n",
       " Document(page_content=\"dehydrogenase, erythrocyte sedimentation rate (ESR), free T 3 , free T 4 and TSH], the presence and duration of Hashimoto's disease, pathological diagnosis and treatment for PTL.\", metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___49', 'num': 49}),\n",
       " Document(page_content=\"The Kaplan-Meier method was used to evaluate the incidence of PTL in patients with Hashimoto's disease. A stepwise procedure at a significance level of 5% was used to construct prognostic models.\", metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___50', 'num': 50}),\n",
       " Document(page_content='SAS version 9.1.3 (SAS Institute Inc., Cary, NC, USA) was used for all statistical analyzes.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___51', 'num': 51}),\n",
       " Document(page_content=\"The patients' characteristics at the time of diagnosis of PTL are shown in Table I. Of the 171 patients, 136 (80%) were female. The median age of the patients was 67 years (range, 27-90 years).\", metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___52', 'num': 52}),\n",
       " Document(page_content=\"Hashimoto's disease was diagnosed in 154 patients (90%).\", metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___53', 'num': 53}),\n",
       " Document(page_content=\"Excluding the 74 patients who had their Hashimoto's disease diagnosed concurrently with their lymphoma, the median interval between the diagnosis of Hashimoto's disease and the diagnosis of PTL was 18\", metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___54', 'num': 54}),\n",
       " Document(page_content='months (range, 1-362 months) in the remaining 80 patients. The median duration of follow-up of the surviving 142 patients was 62AE0 months (range, 0AE1-194AE2 months).', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___55', 'num': 55}),\n",
       " Document(page_content='In 12 of the 142 survivors, the follow-up durations were <100 d due to their transfer to other hospitals.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___56', 'num': 56}),\n",
       " Document(page_content='The 5-year OS and EFS rates of PTL were 85% (95% confidence interval (CI), 79-91%) and 79% (95% CI, 72-86%) respectively (Fig 2).', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___57', 'num': 57}),\n",
       " Document(page_content='The 5-year OS rates of patients with stage I disease and those with stage II disease were 89% (95% CI, 80-91%) and 83% (95% CI, 75-91%), (P = 0AE996) respectively (Fig 3).', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___58', 'num': 58}),\n",
       " Document(page_content='Twenty-nine patients died during followup; lymphoma progression was observed in 10 of the 29 patients.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___59', 'num': 59}),\n",
       " Document(page_content='Thirteen patients died of cerebrovascular disease (n = 3), old age (n = 2), liver failure (n = 2), pneumonia (n = 1), asphyxiation due to aspiration (n = 1), acute myocardial infarction (n = 1), acute', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___60', 'num': 60}),\n",
       " Document(page_content='heart failure (n = 1), bladder cancer (n = 1) and lung cancer (n = 1). Information regarding the cause of death was not available in the remaining six cases.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___61', 'num': 61}),\n",
       " Document(page_content='The pathological diagnosis of PTL patients included DLBCL (n = 74), DLBCL with MALT lymphoma (n = 13) and MALT lymphoma (n = 80).', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___62', 'num': 62}),\n",
       " Document(page_content=\"Patients' characteristics and survival on the basis of pathological diagnosis are shown in Table II; DLBCL and DLBCL with MALT lymphoma were classified as aggressive lymphoma, while MALT lymphoma was\", metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___63', 'num': 63}),\n",
       " Document(page_content='classified as indolent lymphoma. Of the 63 patients with DLBCL, 49 were assigned to the GCB type and 14 to the non-GCB type.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___64', 'num': 64}),\n",
       " Document(page_content='OS was significantly better in patients with the GCB type than in patients with the non-GCB type of PTL (P = 0AE003).', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___65', 'num': 65}),\n",
       " Document(page_content='Of the 167 patients with B-cell lymphoma, information regarding their treatment was available in 161 (Table II). Treatment included CMT (n = 95), RT alone (n = 60) and chemotherapy alone (n = 6).', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___66', 'num': 66}),\n",
       " Document(page_content='Information on treatment response was available in 154 patients; 149 patients (97%) responded to treatment.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___67', 'num': 67}),\n",
       " Document(page_content='According to the institutional treatment strategy of Ito Hospital, 45 of 54 patients with stage IE disease received RT alone and 87 of 113 stage IIE patients received CMT.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___68', 'num': 68}),\n",
       " Document(page_content='Five patients did not respond to initial treatment. Four patients died during follow-up. The causes of death were lymphoma progression (n = 3) and unknown aetiology (n = 1).', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___69', 'num': 69}),\n",
       " Document(page_content='Fifteen patients experienced relapse, which was diagnosed using biopsy (n = 10), computed tomography, ultrasonography and gastroscopy (n = 1).', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___70', 'num': 70}),\n",
       " Document(page_content='Information on diagnostic strategy was not available in four patients. No follow-up information after relapse was available in one patient.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___71', 'num': 71}),\n",
       " Document(page_content=\"Of the remaining 14 patients, six died at a median duration of  There is some overlap between the diseases. àThese included papillary carcinoma (n = 2), Graves' disease (n = 2) and hyperthyroidism (n\", metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___72', 'num': 72}),\n",
       " Document(page_content='= 1).\\n(median [range]) (mm) 21 [0-122] Free T 3 (median [range]) (pmol/l) 4AE9 [1AE8-8AE6] § Free T 4 (median [range]) (pmol/l) 14AE1 [2AE6-36AE1] § TSH (median [range]) (mU/l) 3AE3 [0AE03-', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___73', 'num': 73}),\n",
       " Document(page_content='§Patients with thyroid hormone replacement therapy were excluded. 6AE6 months (range, 1AE8-29AE4 months) after diagnosis of disease progression.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___74', 'num': 74}),\n",
       " Document(page_content=\"These patients' cause of death was progression of lymphoma. Eight patients are presently alive at a median duration of 10AE4 months (range, 0AE5-75AE6 months) after disease progression.\", metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___75', 'num': 75}),\n",
       " Document(page_content='Higher age and higher ESR were significant risk factors for OS. Aggressive lymphoma had a significantly higher hazard ratio than indolent lymphoma with respect to EFS (Table III).', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___76', 'num': 76}),\n",
       " Document(page_content='This study investigated the treatment outcomes of PTL in detail, for which the 5-year OS was 85%.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___77', 'num': 77}),\n",
       " Document(page_content=\"This survival rate was by no means inferior to that of aggressive lymphoma (The International Non-Hodgkin's Lymphoma Prognostic Factors Project, 1993), which has a low risk on the International\", metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___78', 'num': 78}),\n",
       " Document(page_content='prognostic index. We confirmed that treatment outcomes of PTL are favourable, as recent studies suggested (Onal et al, 2010).', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___79', 'num': 79}),\n",
       " Document(page_content='DLBCL can be classified into subgroups with different prognoses: GCB type and non-GCB type, according to cDNA microarray-generated gene-expression profiles (Alizadeh et al, 2000).', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___80', 'num': 80}),\n",
       " Document(page_content='A meta-analysis reported that the GCB type still has a significantly better clinical outcome than the non-GCB type of DLBCL under rituximab-containing chemotherapy (Fang et al, 2010).', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___81', 'num': 81}),\n",
       " Document(page_content='In the present study as well, in which DLBCL patients were assigned to these groups immunohistologically, the prognosis of GCB type patients was better than that of non-GCB type patients, as', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___82', 'num': 82}),\n",
       " Document(page_content='previously reported (Niitsu et al, 2007). Thus, subgrouping by immunohistological techniques is probably useful in PTL for identifying patients with poor prognosis.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___83', 'num': 83}),\n",
       " Document(page_content='In addition to the prognostic factors that have been reported in nodal lymphomas, such as age and pathological diagnosis, §Treatment for these patients included CHOP with or without rituximab (n = 4),', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___84', 'num': 84}),\n",
       " Document(page_content='COP-BLAM (n = 1), local irradiation (n = 1), ESHAP, etoposide, methylprednisolone, cytaravine and cisplatin (n = 1), IMVP-16, ifosofamide, methotrexate and etoposide with irradiation (n = 2) and', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___85', 'num': 85}),\n",
       " Document(page_content='rituximab (n = 1). Information was not available for the remaining seven patients.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___86', 'num': 86}),\n",
       " Document(page_content='ESR was shown to be a prognostic indicator in this study.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___87', 'num': 87}),\n",
       " Document(page_content=\"It has been reported that ESR, which is routinely measured as an index of disease progression at Ito Hospital, reflects disease progression in patients with Hashimoto's disease (Shigemasa et al, 1990;\", metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___88', 'num': 88}),\n",
       " Document(page_content='Kon & DeGroot, 2003).', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___89', 'num': 89}),\n",
       " Document(page_content=\"This result indicates that the progression of Hashimoto's disease is associated with that of PTL, supporting the possibility that Hashimoto's disease is part of an immune reaction that evokes PTL.\", metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___90', 'num': 90}),\n",
       " Document(page_content=\"This may be an important finding for elucidating the relationship between Hashimoto's disease and PTL.\", metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___91', 'num': 91}),\n",
       " Document(page_content=\"This study revealed, for the first time, that the age of patients with PTL at the time of the initial hospital visit for Hashimoto's disease was higher than that of non-lymphoma patients.\", metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___92', 'num': 92}),\n",
       " Document(page_content=\"Considering that age was an independent prognostic factor in the analysis of risk factors in this study, indicating that when examining older patients during their initial consultation for Hashimoto's\", metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___93', 'num': 93}),\n",
       " Document(page_content='disease, clinicians must be aware that there is a high risk of the occurrence of PTL in these older patients.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___94', 'num': 94}),\n",
       " Document(page_content=\"This large-scale long-term observational study confirmed the important relationship between Hashimoto's disease and PTL; patients with Hashimoto's disease were at higher risk for PTL than the general\", metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___95', 'num': 95}),\n",
       " Document(page_content='population, as previous studies suggested (Holm et al, 1985;Kato et al, 1985).', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___96', 'num': 96}),\n",
       " Document(page_content=\"In this study, the  incidence rate of PTL in patients with Hashimoto's disease was about 16 persons/year per 10 000 persons, which is much higher than the incidence rate of PTL in the Japanese general\", metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___97', 'num': 97}),\n",
       " Document(page_content='population (0AE02 persons/year per 10 000 persons) (Kato et al, 1985).', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___98', 'num': 98}),\n",
       " Document(page_content=\"Further, the incidence rate of PTL among patients with Hashimoto's disease in this study was about 10 times higher than that reported in a previous small-scale study (Holm et al, 1985;Kato et al, 1985\", metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___99', 'num': 99}),\n",
       " Document(page_content='). Two possibilities may explain this discrepancy. First, Ito Hospital is a specialized hospital for thyroid disease, so that selection bias may have been possible.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___100', 'num': 100}),\n",
       " Document(page_content=\"[0AE54-2AE60] (0AE68) 1AE68 [0AE87-3AE19] (0AE12) Hoarseness 1AE31 [0AE49-3AE47] (0AE59) 1AE76 [0AE73-4AE22] (0AE21) Dyspnoea 1AE13 [0AE34-3AE77] (0AE84) 1AE79 [0AE84-3AE82] (0AE13) Hashimoto's\", metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___101', 'num': 101}),\n",
       " Document(page_content='disease 2AE21 [0AE30-16AE4] (0AE44) 1AE55 [0AE37-6AE45] (', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___102', 'num': 102}),\n",
       " Document(page_content=\"In the case of Ito Hospital, more than 50% of all patients are referred from other centres (data not shown), but usually 80-90% of all patients with Hashimoto's disease have no symptoms (Dayan &\", metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___103', 'num': 103}),\n",
       " Document(page_content='Daniels, 1996), and many such patients are followed-up at a nearby hospital.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___104', 'num': 104}),\n",
       " Document(page_content='Therefore, we cannot rule out the possibility that complicated cases may have been selectively referred to Ito Hospital, resulting in overestimation of the incidence of PTL.', metadata={'source': 'Clinicopathological features of 171 cases of primary thyroid lymphoma_ a long_term study involving 24_553 patients with Hashimoto_s disease.json___105', 'num': 105}),\n",
       " ...]"
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "texts"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "# # metas=list(map(lambda el: f\"{el.metadata['source']}___{el.metadata['num']}\",texts))\n",
    "# metas=list(map(lambda el: el.metadata,texts))\n",
    "# metas"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "# vectorstore = Chroma(embedding_function=embeddings, persist_directory=\"/data\")\n",
    "# vectorstore = FAISS.from_documents(list(map(lambda el: el.page_content,texts)), embedding=embeddings)\n",
    "vectorstore = FAISS.from_documents(texts, embedding=embeddings)\n",
    "vectorstore.save_local(\"/data/faiss_index\")\n",
    "# This text splitter is used to create the child documents\n",
    "# child_splitter = RecursiveCharacterTextSplitter(chunk_size=400)\n",
    "# store = InMemoryStore()\n",
    "# retriever = vectorstore.as_retriever(search_kwargs=dict(k=5))\n",
    "retriever = vectorstore.as_retriever()\n",
    "\n",
    "# # store = InMemoryStore()\n",
    "# retriever = ParentDocumentRetriever(\n",
    "#     vectorstore=vectorstore,\n",
    "#     docstore=store,\n",
    "#     child_splitter=child_splitter,\n",
    "# )\n",
    "# retriever.add_documents(res, ids=metas)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# chunks = res[0:2]\n",
    "# chunks=res\n",
    "\n",
    "vector_qa = RetrievalQAWithSourcesChain.from_chain_type(\n",
    "    llm=llm_med,\n",
    "    chain_type=\"stuff\",\n",
    "    retriever=retriever,\n",
    "    return_source_documents=True\n",
    ")\n",
    "\n",
    "\n",
    "# https://github.com/langchain-ai/langchain/issues/5642"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "result = vector_qa({\"question\": \"as an expert in endocrinology and nuclear medicine what are indications to monitor thyroid cancer patients with thyroglobulin and what are the limitations of thyroglobulin as a tumor marker?\"})\n",
    "result"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Store the chunks part in db (vector)\n",
    "\n",
    "# vectorstore = Neo4jVector.from_texts(\n",
    "#     chunks,\n",
    "#     url=url,\n",
    "#     username=username,\n",
    "#     password=password,\n",
    "#     embedding=embeddings,\n",
    "#     index_name=\"pdf_bot\",\n",
    "#     node_label=\"PdfBotChunk\",\n",
    "#     pre_delete_collection=True,  # Delete existing PDF data\n",
    "# )\n",
    "\n",
    "# vectorstore = Chroma(embedding_function=embeddings, persist_directory=\"/data\")\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# vector_qa = RetrievalQAWithSourcesChain.from_chain_type(\n",
    "#     llm=llm_med,\n",
    "#     chain_type=\"stuff\",\n",
    "#     retriever=retriever\n",
    "# )\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# result = vector_qa({\"question\": \"what is RIT\"})\n",
    "# result"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.12"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
